

Spironolactone for Heart Failure with Preserved Ejection

New England Journal of Medicine

370, 1383-1392

DOI: [10.1056/nejmoa1313731](https://doi.org/10.1056/nejmoa1313731)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Heart failure with preserved ejection fraction. <i>Clinical Medicine</i> , 2014, 14, s22-s28.	0.8	15
3	Effect of fluid and dietary sodium restriction in the management of patients with heart failure and preserved ejection fraction: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 347.	0.7	5
4	Management considerations in the care of elderly heart failure patients in long-term care facilities. <i>Future Cardiology</i> , 2014, 10, 563-577.	0.5	12
5	Insuficiencia cardíaca. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2014, 21, 9-36.	0.0	0
6	Heart Failure: Gaps in Knowledge and Failures in Treatment. <i>PLoS Medicine</i> , 2014, 11, e1001702.	3.9	4
7	Lessons from the TOPCAT Trial. <i>New England Journal of Medicine</i> , 2014, 370, 1453-1454.	13.9	47
8	Geographic variation in heart failure trials: time for scepticism?. <i>European Journal of Heart Failure</i> , 2014, 16, 601-602.	2.9	17
9	The Epidemic of Heart Failure: A Lucid Approach to Stemming the Rising Tide. <i>Canadian Journal of Cardiology</i> , 2014, 30, S442-S454.	0.8	14
10	Murine Models of Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2014, 20, 984-995.	0.7	83
11	Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. <i>European Journal of Heart Failure</i> , 2014, 16, 796-801.	2.9	106
12	Effects of long-term endurance and resistance training on diastolic function, exercise capacity, and quality of life in asymptomatic diastolic dysfunction vs. heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2014, 1, 59-74.	1.4	19
13	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	1.2	424
14	Recent Developments in Cardiovascular Stem Cells. <i>Circulation Research</i> , 2014, 115, e71-8.	2.0	29
15	The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). <i>European Journal of Heart Failure</i> , 2014, 16, 1049-1055.	2.9	172
16	Heart Failure with Preserved Ejection Fraction. , 2014, , 193-203.		2
17	Impaired Myocardial Oxygen Availability Contributes to Abnormal Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2014, 3, e001293.	1.6	47
18	Is there a new dawn for selective mineralocorticoid receptor antagonism?. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 456-461.	1.0	12
19	The journey of the frail older adult with heart failure: implications for management and health care systems. <i>Reviews in Clinical Gerontology</i> , 2014, 24, 269-289.	0.5	13

#	ARTICLE	IF	CITATIONS
20	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	1.6	218
21	Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 449-455.	1.0	5
22	Regional Variability in β -Blocker Efficacy and Safety: A Question of "Location, Location, Location". <i>Canadian Journal of Cardiology</i> , 2014, 30, 858-860.	0.8	0
23	Optimising exercise training in prevention and treatment of diastolic heart failure (OptimEx-CLIN): rationale and design of a prospective, randomised, controlled trial. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 18-25.	0.8	61
24	Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes. <i>Current Heart Failure Reports</i> , 2014, 11, 416-427.	1.3	46
25	Cardiac effects of aldosterone: Does gender matter?. <i>Steroids</i> , 2014, 91, 32-37.	0.8	22
26	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. <i>Current Cardiology Reports</i> , 2014, 16, 545.	1.3	23
27	Spironolactone for Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2014, 371, 179-182.	13.9	25
28	New Drugs and Devices in the Pipeline for Heart Failure with Reduced Ejection Fraction Versus Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2014, 11, 374-381.	1.3	7
29	Insuffisance cardiaque. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2014, 2014, 47.	0.0	0
30	Diagnosis of Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 399-406.	1.0	20
31	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
32	Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2014, 176, 321-326.	0.8	8
33	Misconceptions and Facts About "Diastolic" Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 1144-1147.	0.6	4
34	Mineralcorticoid Antagonists in Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 559-564.	1.0	4
35	Management Strategies for Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 591-598.	1.0	12
36	Do Current Clinical Trials Meet Society's Needs?. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1615-1628.	1.2	53
38	Heart Failure With Preserved Ejection Fraction. <i>Circulation Research</i> , 2014, 115, 79-96.	2.0	410

#	ARTICLE	IF	CITATIONS
39	The Heart Failure Paradox: An Epidemic of Scientific Success. <i>Circulation</i> , 2014, 129, 2717-2722.	1.6	12
40	Newest additions to heart failure treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1849-1861.	0.9	1
41	Epidemiology of Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2014, 11, 354-365.	1.3	91
42	10 Years of progress in HF research—what have we learned?. <i>Nature Reviews Cardiology</i> , 2014, 11, 631-633.	6.1	4
43	Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2014, 20, 560-568.	0.7	38
44	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	1.2	34
45	103, 106a-106a.	0.0	0
47	Review of the top 5 cardiology studies of 2013-14. <i>Canadian Pharmacists Journal</i> , 2015, 148, 349-354.	0.4	3
48	Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2015, 2, 41-45.	1.4	15
49	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the "Preserve" study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	2.9	52
50	Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the "ASTRONAUT" trial. <i>European Journal of Heart Failure</i> , 2015, 17, 591-600.	2.9	58
51	Maintenance of serum potassium with sodium zirconium cyclosilicate ("ZS") in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1050-1056.	2.9	143
52	Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. <i>European Journal of Heart Failure</i> , 2015, 17, 1252-1261.	2.9	95
53	Enabling a Learning Health System through a Unified Enterprise Data Warehouse: The Experience of the Northwestern University Clinical and Translational Sciences (NUCATS) Institute. <i>Clinical and Translational Science</i> , 2015, 8, 269-271.	1.5	61
54	Diastolic Dysfunction. <i>Circulation Journal</i> , 2015, 79, 470-477.	0.7	129
55	Current Challenges in the Management of Heart Failure. <i>Circulation Journal</i> , 2015, 79, 948-953.	0.7	25
56	Left Ventricular Ejection Fraction (EF) of 55% as Cutoff for Late Transition From Heart Failure (HF) With Preserved EF to HF With Mildly Reduced EF. <i>Circulation Journal</i> , 2015, 79, 2209-2215.	0.7	35
57	Towards "Eternal Youth"™ of cardiac and skeletal muscle. <i>Global Cardiology Science & Practice</i> , 2015, 12.	0.3	0

#	ARTICLE	IF	CITATIONS
58	What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?. Open Heart, 2015, 2, e000283.	0.9	13
59	Update of treatment in chronic heart failure. Medicina Clínica (English Edition), 2015, 145, 545-550.	0.1	1
61	Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H986-H994.	1.5	24
62	Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. Methodist DeBaake Cardiovascular Journal, 2021, 11, 235.	0.5	30
63	Heart failure as a general pandemic in Asia. European Journal of Heart Failure, 2015, 17, 884-892.	2.9	311
64	Geographic differences in heart failure trials. European Journal of Heart Failure, 2015, 17, 893-905.	2.9	64
65	Intercellular communication lessons in heart failure. European Journal of Heart Failure, 2015, 17, 1091-1103.	2.9	47
66	Effect of low-dose diuretics on the level of serum cystatin C and prognosis in patients with asymptomatic chronic heart failure. Experimental and Therapeutic Medicine, 2015, 10, 2345-2350.	0.8	4
67	Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2015, 30, 250-258.	0.8	29
68	Chronic heart failure. Current Opinion in Cardiology, 2015, 30, 344-353.	0.8	4
69	Heart Failure With Preserved Ejection Fraction. Journal of Osteopathic Medicine, 2015, 115, 432-442.	0.4	9
70	Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction. BioMed Research International, 2015, 2015, 1-7.	0.9	15
71	Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians. Hospital Pharmacy, 2015, 50, 454-459.	0.4	9
72	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vascular Health and Risk Management, 2015, 11, 283.	1.0	17
73	Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania. Clinical Interventions in Aging, 2015, 10, 979.	1.3	9
74	Treatment Modalities for Heart Failure with Preserved Ejection Fraction (HFpEF) - Current State of Evidence and Future Perspective. Journal of Clinical & Experimental Cardiology, 2015, 06, .	0.0	0
75	Recent advances in treatment of heart failure. F1000Research, 2015, 4, 1475.	0.8	11
76	What is Heart Failure?. Journal of the Nihon University Medical Association, 2015, 74, 153-160.	0.0	0

#	ARTICLE	IF	CITATIONS
77	Inflammation in Heart Failure with Preserved Ejection Fraction. , 2015, , 3-18.		3
79	β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. Journal of Cardiology, 2015, 66, 189-194.	0.8	15
80	Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders. Current Hypertension Reports, 2015, 17, 52.	1.5	24
81	Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends in Endocrinology and Metabolism, 2015, 26, 201-211.	3.1	27
82	International Collaboration: Promises and Challenges. Rambam Maimonides Medical Journal, 2015, 6, e0012.	0.4	10
83	Heart failure: key points and recent developments in management. The Prescriber, 2015, 26, 25-31.	0.1	2
84	National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE) Retrospective AMI Study, 2001, 2006, and 2011. Journal of the American Heart Association, 2015, 4, e001718.	1.6	7
85	Aldosterone and Left Ventricular Remodeling. Hormone and Metabolic Research, 2015, 47, 981-986.	0.7	41
86	Pharmacotherapy of feline cardiomyopathy: chronic management of heart failure. Journal of Veterinary Cardiology, 2015, 17, S159-S172.	0.3	11
87	Heart failure with preserved ejection fraction: Refocusing on diastole. International Journal of Cardiology, 2015, 179, 430-440.	0.8	91
88	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. Canadian Journal of Cardiology, 2015, 31, 3-16.	0.8	96
89	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation, 2015, 131, 34-42.	1.6	758
90	2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. Journal of the Chinese Medical Association, 2015, 78, 1-47.	0.6	183
91	Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology, 2015, 31, 430-439.	0.8	31
92	Heart failure: the cardiovascular epidemic of the 21st century. European Heart Journal, 2015, 36, 395-397.	1.0	33
93	Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2015, 183, 33-38.	0.8	27
94	Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation, 2015, 131, 1247-1259.	1.6	509
95	Mixed results for heart failure therapies. Nature Reviews Cardiology, 2015, 12, 73-75.	6.1	3

#	ARTICLE	IF	CITATIONS
96	Developing Imaging Biomarkers for Myocardial Involvement in Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 60-62.	2.3	2
97	Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. <i>Circulation Research</i> , 2015, 116, 206-213.	2.0	73
98	Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. <i>Hypertension</i> , 2015, 65, 257-263.	1.3	169
99	Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry. <i>American Heart Journal</i> , 2015, 169, 713-720.e3.	1.2	11
100	Mineralocorticoid Receptor Antagonism Treats Obesity-Associated Cardiac Diastolic Dysfunction. <i>Hypertension</i> , 2015, 65, 1082-1088.	1.3	84
102	Espironolactona en pacientes con insuficiencia cardiaca y fracci3n de eyecci3n preservada. <i>Revista Clinica Espanola</i> , 2015, 215, 301-307.	0.2	3
103	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015, 20, 375-383.	1.7	13
104	Actualizaci3n 2014 en cardiologÃa clÃnica, cardiologÃa geriÃtrica e insuficiencia cardiaca y trasplante. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 317-323.	0.6	6
105	Worsening diastolic function is associated with elevated fasting plasma glucose and increased left ventricular mass in a supra-additive fashion in an elderly, healthy, Swedish population. <i>International Journal of Cardiology</i> , 2015, 184, 466-472.	0.8	14
106	Regional Differences in Heart Failure With Preserved Ejection Fraction Trials. <i>Circulation</i> , 2015, 131, 7-10.	1.6	27
107	Small molecule and peptide therapies for chronic heart failure: a patent review (2011 â€“ 2014). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 1175-1190.	2.4	5
108	Pharmacological treatment of aldosterone excess. , 2015, 154, 120-133.		31
109	Management of hypertension in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 555-563.	4.1	59
110	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015, 116, 1304-1310.	0.7	5
111	Heart Failure as a Newly Approved Diagnosis for Cardiac Rehabilitation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2652-2659.	1.2	77
112	Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. <i>Cellular Physiology and Biochemistry</i> , 2015, 36, 1453-1466.	1.1	35
113	Review of heart failure treatment in type2 diabetes patients: It's at least as effective as in non-diabetic patients!. <i>Diabetes and Metabolism</i> , 2015, 41, 446-455.	1.4	10
115	Spironolactone in patients with heart failure and preserved ejection fraction. <i>Revista ClÃnica Espanola</i> , 2015, 215, 301-307.	0.3	0

#	ARTICLE	IF	CITATIONS
116	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2015, 3, 603-614.	1.9	36
117	Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. <i>Circulation</i> , 2015, 132, 923-931.	1.6	397
118	The Safety of Eplerenone in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1602-1608.	2.2	50
119	Clinical characteristics and outcomes of patients with angina and heart failure in the <sc>CHARM</sc> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314. <i>BT / Overlock 10</i>	1.6	371
120	Low Fitness in Midlife: A Novel Therapeutic Target for Heart Failure with Preserved Ejection Fraction Prevention. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 87-93.	1.6	24
122	Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. <i>American Journal of Medicine</i> , 2015, 128, 1275-1280.	0.6	58
123	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015, 132, 402-414.	1.6	371
124	Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-Na ^{-ve} Patients With Hypertension. <i>Hypertension</i> , 2015, 65, 1231-1237.	1.3	31
126	Heart Failure with Preserved Ejection Fraction. <i>Hospital Medicine Clinics</i> , 2015, 4, 283-296.	0.2	0
127	Eplerenone's role in the management of complex cardiovascular disorders. <i>International Journal of Cardiology</i> , 2015, 200, 1-2.	0.8	6
128	Non-sirtuin histone deacetylases in the control of cardiac aging. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 83, 14-20.	0.9	44
129	International REgistry to assess medical Practice with LOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. <i>European Journal of Heart Failure</i> , 2015, 17, 527-533.	2.9	52
130	Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	0
131	Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H1126-H1135.	1.5	64
132	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	0.6	10
133	The year in cardiology: heart failure 2014. <i>European Heart Journal</i> , 2015, 36, 421-424.	1.0	3
134	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	1.2	20
136	Heart failure with preserved ejection fraction in the elderly: scope of the problem. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 83, 73-87.	0.9	113

#	ARTICLE	IF	CITATIONS
137	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 480-487.	0.2	4
139	Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. <i>European Heart Journal</i> , 2015, 36, 1718-1727.	1.0	392
140	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	1.2	168
141	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	1.2	116
142	Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER). <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 179-185.	1.3	9
143	LCZ696: The Next Step in Improving RAS Inhibition?. <i>Current Hypertension Reports</i> , 2015, 17, 37.	1.5	7
146	Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. <i>BMC Medicine</i> , 2015, 13, 10.	2.3	27
147	Pharmacotherapy of Heart Failure with Preserved Ejection Fraction. <i>Pharmacotherapy</i> , 2015, 35, 351-360.	1.2	19
148	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.	1.9	72
150	Update on management of heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2015, 30, 173-178.	0.8	6
151	Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2015, 30, 168-172.	0.8	10
152	Update for 2014 on Clinical Cardiology, Geriatric Cardiology, and Heart Failure and Transplantation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 317-323.	0.4	5
153	Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. <i>American Journal of Cardiology</i> , 2015, 116, 155-161.	0.7	33
154	Role of the Renin-Angiotensin-Aldosterone System in the Management of Neonatal Heart Failure. <i>NeoReviews</i> , 2015, 16, e575-e585.	0.4	2
155	Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. <i>Heart Failure Reviews</i> , 2015, 20, 643-653.	1.7	68
156	Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). <i>International Journal of Cardiology</i> , 2015, 200, 15-19.	0.8	16
157	Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, 1719-1725.	1.6	119
158	An Update on Inpatient Hypertension Management. <i>Current Cardiology Reports</i> , 2015, 17, 94.	1.3	23

#	ARTICLE	IF	CITATIONS
159	Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. <i>Journal of the American Heart Association</i> , 2015, 4, e002137.	1.6	52
160	The Role of Nephilysin Inhibitors in Cardiovascular Disease. <i>Current Heart Failure Reports</i> , 2015, 12, 389-394.	1.3	16
161	The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1017-1030.	0.6	37
162	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2015, 21, 674-693.	0.7	39
163	Heart failure with preserved ejection fraction: uncertainties and dilemmas. <i>European Journal of Heart Failure</i> , 2015, 17, 665-671.	2.9	124
164	Hospitalized Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 591-601.	1.0	3
165	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	1.6	70
166	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 64.	2.0	15
168	Fundamentals of Clinical Trials. , 2015, , .		603
169	Mineralocorticoid Receptor Antagonism in Acute Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 402.	0.4	3
170	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. <i>Current Heart Failure Reports</i> , 2015, 12, 318-327.	1.3	10
172	Cardiac Imaging to Evaluate Left Ventricular Diastolic Function. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1071-1093.	2.3	160
174	Management of Heart Failure With Preserved Ejection Fraction: A Review. <i>Clinical Therapeutics</i> , 2015, 37, 2186-2198.	1.1	30
175	Containing the Cost of Heart Failure Management. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 577-584.	0.7	6
176	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.	1.9	21
177	El tratamiento de la insuficiencia cardiaca con fracción de eyección preservada. Un problema sin resolver. <i>Revista Clinica Espanola</i> , 2015, 215, 320-321.	0.2	2
178	Improving outcomes in heart failure: a personal perspective. <i>European Heart Journal</i> , 2015, 36, 3467-3470.	1.0	41
180	What global diastolic function is, what it is not, and how to measure it. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H1392-H1406.	1.5	25

#	ARTICLE	IF	CITATIONS
181	Machine Learning in Medicine. <i>Circulation</i> , 2015, 132, 1920-1930.	1.6	1,923
182	Discovery of <i>N</i> -[5-(6-Chloro-3-cyano-1-methyl-1 <i>H</i> -indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9382-9394.	2.9	22
183	Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?. <i>Heart Failure Reviews</i> , 2015, 20, 283-290.	1.7	13
184	Mineralocorticoids in the Heart and Vasculature: New Insights for Old Hormones. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 289-312.	4.2	48
185	Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones:biomarkers or mediators. <i>Clinica Chimica Acta</i> , 2015, 443, 3-8.	0.5	30
186	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 29-38.	0.5	70
187	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
188	Cardiac Drug Therapy. <i>Contemporary Cardiology</i> , 2015, , .	0.0	4
189	A 70-year-old woman with heart failure with preserved ejection fraction. <i>Cmaj</i> , 2015, 187, 510-511.	0.9	2
190	Differential diagnosis and clinical management of diastolic heart failure: current best practice. <i>Research Reports in Clinical Cardiology</i> , 2016, Volume 7, 117-135.	0.2	2
191	Heart Failure in Patients with Preserved Ejection Fraction: Questions Concerning Clinical Progression. <i>Journal of Cardiovascular Development and Disease</i> , 2016, 3, 27.	0.8	6
192	Advances in the management of heart failure: the role of ivabradine. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 453-470.	1.0	20
193	Targeting heart failure with preserved ejection fraction: current status and future prospects. <i>Vascular Health and Risk Management</i> , 2016, 12, 129.	1.0	24
194	MicroRNA and Heart Failure. <i>International Journal of Molecular Sciences</i> , 2016, 17, 502.	1.8	98
195	Does Aldosterone Play a Significant Role for Regulation of Vascular Tone?. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 68, 1-10.	0.8	15
196	Contemporary clinical trial updates in heart failure. <i>Current Opinion in Cardiology</i> , 2016, 31, 349-355.	0.8	1
197	Diastolic heart failure. <i>Current Opinion in Anaesthesiology</i> , 2016, 29, 61-67.	0.9	19
198	Baroreflex failure increases the risk of pulmonary edema in conscious rats with normal left ventricular function. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H199-H205.	1.5	13

#	ARTICLE	IF	CITATIONS
199	Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. <i>Open Heart</i> , 2016, 3, e000449.	0.9	14
200	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	113
201	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 79-108.	0.9	7
202	Understanding acute heart failure: pathophysiology and diagnosis. <i>European Heart Journal Supplements</i> , 2016, 18, G11-G18.	0.0	32
203	The Three-Decade Long Journey in Heart Failure Drug Development. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 1-14.	0.9	12
204	Natriuretic Peptides, 6-Min Walk Test, andÂQuality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2690-2707.	1.2	83
205	Interpreting Geographic Variations in Results of Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , 2016, 375, 2263-2271.	13.9	71
206	Diagnosis and management of heart disease in the elderly. , 2016, , 157-186.		0
208	The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians. <i>Postgraduate Medical Journal</i> , 2016, 92, 346-355.	0.9	6
209	Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 246.	0.7	37
210	Understanding heart failure with preserved ejection fraction: where are we today?. <i>Netherlands Heart Journal</i> , 2016, 24, 227-236.	0.3	71
211	Ambulatory Blood Pressure Parameters and Heart Failure With Reduced or Preserved Ejection Fraction in Elderly Treated Hypertensive Patients. <i>American Journal of Hypertension</i> , 2016, 29, 1001-1007.	1.0	14
212	Nonagenarians presenting to the diagnostic heart failure clinic. <i>European Geriatric Medicine</i> , 2016, 7, 28-33.	1.2	3
213	Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials. <i>Thrombosis Research</i> , 2016, 144, 32-39.	0.8	4
214	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
215	The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 659-665.	1.0	13
216	Geriatric Heart Failure: A Call for Papers. <i>Journal of Cardiac Failure</i> , 2016, 22, 247-248.	0.7	1
217	After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. <i>European Heart Journal</i> , 2016, 37, 3135-3140.	1.0	23

#	ARTICLE	IF	CITATIONS
218	The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. <i>International Journal of Cardiology</i> , 2016, 214, 301-306.	0.8	50
219	Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2529-2542.	3.0	49
220	How big a problem is heart failure with a normal ejection fraction?. <i>BMJ, The</i> , 2016, 353, i1706.	3.0	10
221	Imaging for assessment of sudden death risk: current role and future prospects. <i>Europace</i> , 2016, 18, 1491-1500.	0.7	7
222	Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1815-1825.	1.2	165
223	Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?. <i>Current Hypertension Reports</i> , 2016, 18, 41.	1.5	32
224	Constrictive Pericarditis Versus Restrictive Cardiomyopathy?. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2061-2076.	1.2	76
225	Diastolic dysfunction in anaesthesia and critical care. <i>BJA Education</i> , 2016, 16, 287-291.	0.6	6
226	QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 477-486.	1.9	38
227	Detection and Management of Geographic Disparities in the TOPCAT Trial. <i>JACC Basic To Translational Science</i> , 2016, 1, 180-189.	1.9	50
228	Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis. <i>Age and Ageing</i> , 2016, 46, 18-25.	0.7	11
229	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	12
230	Left ventricular twist mechanics in the context of normal physiology and cardiovascular disease: a review of studies using speckle tracking echocardiography. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H633-H644.	1.5	67
231	Insulin-Like Growth Factor Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 860-869.	1.9	58
232	Turning the Retrospectroscope on Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2016, 22, 1023-1027.	0.7	4
233	Understanding the Role of <i>P</i> Values and Hypothesis Tests in Clinical Research. <i>JAMA Cardiology</i> , 2016, 1, 1048.	3.0	53
234	JACC: Basic to Translational Science. <i>JACC Basic To Translational Science</i> , 2016, 1, 190-191.	1.9	1
235	Transforming Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	8

#	ARTICLE	IF	CITATIONS
236	A tentative interpretation of the <scp>TOPCAT</scp> trial based on randomized evidence from the brain natriuretic peptide stratum analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1411-1414.	2.9	31
237	Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	178
238	Acute decompensated heart failure (ADHF): A comprehensive contemporary review on preventing early readmissions and postdischarge death. <i>International Journal of Cardiology</i> , 2016, 223, 1035-1044.	0.8	25
239	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: Rationale and Study Design of a Prospective Randomized Controlled Trial. <i>Clinical Cardiology</i> , 2016, 39, 433-439.	0.7	8
240	Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. <i>International Journal of Cardiology</i> , 2016, 222, 569-575.	0.8	6
241	Pharmacology of heart failure: From basic science to novel therapies. , 2016, 166, 136-149.		18
242	Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-blind, Randomized, Placebo-controlled Trial. <i>Clinical Cardiology</i> , 2016, 39, 285-290.	0.7	8
243	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016, 18, 54-65.	2.9	73
244	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
245	Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. <i>British Journal of Pharmacology</i> , 2016, 173, 1911-1924.	2.7	14
246	Globalization of heart failure trials: no turning back on this paradigm. <i>European Heart Journal</i> , 2016, 37, 3175-3177.	1.0	4
247	Rationale and design of the <scp>PREFERS</scp> (Preserved and Reduced Ejection Fraction) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Stockholm county of 2.1 million inhabitants. <i>European Journal of Heart Failure</i> , 2016, 18, 1287-1297.	2.9	17
248	The Primary Outcome Fails â€” What Next?. <i>New England Journal of Medicine</i> , 2016, 375, 861-870.	13.9	204
249	Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	42
250	Relation Between Echocardiogram-Based Cardiac Parameters and Outcome in Heart Failure With Preserved and Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2016, 118, 1356-1362.	0.7	20
251	The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases. <i>Future Medicinal Chemistry</i> , 2016, 8, 1533-1536.	1.1	2
252	Reducing RBM20 activity improves diastolic dysfunction and cardiac atrophy. <i>Journal of Molecular Medicine</i> , 2016, 94, 1349-1358.	1.7	48
253	What constitutes optimal neurohumoral antagonism in chronic heart failure?. <i>Heart</i> , 2016, 102, 1922-1932.	1.2	3

#	ARTICLE	IF	CITATIONS
254	N-Terminal pro-B-type natriuretic peptide is a useful marker to identify latent heart failure patients in older adults in a rural outpatient clinic. <i>Geriatrics and Gerontology International</i> , 2017, 17, 1648-1653.	0.7	1
255	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	33
256	Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension. <i>JAMA Cardiology</i> , 2016, 1, 607.	3.0	14
257	Does left ventricular diastolic dysfunction progress through stages? Insights from a community heart failure study. <i>International Journal of Cardiology</i> , 2016, 221, 850-854.	0.8	11
258	Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	99
259	Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1823-1834.	1.2	92
260	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	1.0	36
261	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 271-305.	0.9	102
262	Novel insights in HFrEF and HFpEF: patient characteristics, remote monitoring, and management. <i>European Heart Journal</i> , 2016, 37, 3117-3120.	1.0	0
263	Pharmacogenomics of heart failure: a systematic review. <i>Pharmacogenomics</i> , 2016, 17, 1817-1858.	0.6	10
264	If Exercise Is the Best Medicine, Should Medicine Be More Focused on Exercise in HFpEF? <i>Journal of the American College of Cardiology</i> , 2016, 68, 1835-1837.	1.2	0
265	How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. <i>Current Cardiology Reports</i> , 2016, 18, 122.	1.3	27
266	Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1097-1107.	0.8	25
267	Myocardial reverse remodeling: how far can we rewind?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H1402-H1422.	1.5	32
268	Cardiac Diastolic Dysfunction is Associated With Aortic Wave Reflection, but Not Stiffness in a Predominantly Young-to-Middle-Aged Community Sample. <i>American Journal of Hypertension</i> , 2016, 29, 1148-1157.	1.0	19
269	The Established Therapies: HF-PEF and HF-REF. , 2016, , 1-27.		0
270	Role of Angiotensin Receptor-Nepriylisin Inhibition in Heart Failure. <i>Current Atherosclerosis Reports</i> , 2016, 18, 48.	2.0	10
271	Impact of Sleep-Disordered Breathing on Long-Term Outcomes in Patients With Acute Coronary Syndrome Who Have Undergone Primary Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	38

#	ARTICLE	IF	CITATIONS
272	Diet and Exercise for Obese Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2016, 315, 2618.	3.8	0
273	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	26
274	Prolonged QRS in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 487-489.	1.9	0
275	Intrafamilial aggregation and heritability of tissue Doppler indexes of left ventricular diastolic function in a group of African descent. Journal of the American Society of Hypertension, 2016, 10, 517-526.e11.	2.3	2
276	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 591-598.	2.1	74
277	Vascular Mineralocorticoid Receptors. Hypertension, 2016, 68, 6-10.	1.3	28
278	Impact of hyperkalaemia definition on incidence assessment: implications for epidemiological research based on a large cohort study in newly diagnosed heart failure patients in primary care. BMC Family Practice, 2016, 17, 51.	2.9	7
279	Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. International Journal of Cardiology, 2016, 220, 56-60.	0.8	23
280	Development of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Progress in Cardiovascular Diseases, 2016, 59, 52-58.	1.6	14
281	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation, 2016, 134, 73-90.	1.6	747
282	From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure. Heart Lung and Circulation, 2016, 25, 425-434.	0.2	14
283	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. Heart Failure Reviews, 2016, 21, 455-462.	1.7	26
284	Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF). Journal of Cardiac Failure, 2016, 22, 539-544.	0.7	25
285	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	93
286	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal, 2016, 37, 455-462.	1.0	396
287	New Targets in the Drug Treatment of Heart Failure. Drugs, 2016, 76, 187-201.	4.9	2
288	Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology, 2016, 23, 78-85.	0.8	84
289	Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clinical Research in Cardiology, 2016, 105, 489-507.	1.5	35

#	ARTICLE	IF	CITATIONS
290	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.3	238
291	Impact of Race, Ethnicity, and Multimodality Biomarkers on the Incidence of New-Onset Heart Failure With Preserved Ejection Fraction (from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2016, 117, 1474-1481.	0.7	54
292	Heart failure “ what the general physician needs to know. Clinical Medicine, 2016, 16, 25-33.	0.8	1
293	Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2016, 5, .	1.6	97
294	New Management Strategies in Heart Failure. Circulation Research, 2016, 118, 480-495.	2.0	37
295	Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2016, 1, 7.	3.0	35
296	Multimorbidity in Older Adults with Heart Failure. Clinics in Geriatric Medicine, 2016, 32, 277-289.	1.0	22
297	Heart Failure With Preserved Ejection Fraction. Current Problems in Cardiology, 2016, 41, 145-188.	1.1	107
299	Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circulation: Heart Failure, 2016, 9, e001937.	1.6	71
300	Roles of Aldosterone Receptor Antagonists in Heart Failure, Hypertension, and Chronic Kidney Disease. Journal for Nurse Practitioners, 2016, 12, 201-206.	0.4	5
301	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. Heart, 2016, 102, 320-330.	1.2	29
302	Renin“angiotensin“aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. International Journal of Cardiology, 2016, 205, 65-71.	0.8	23
303	Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. Circulation: Heart Failure, 2016, 9, e002724.	1.6	49
304	Defining HFpEF: where do we draw the line?. European Heart Journal, 2016, 37, 463-465.	1.0	25
305	Cardiac GR and MR: From Development to Pathology. Trends in Endocrinology and Metabolism, 2016, 27, 35-43.	3.1	29
306	Effects of renin“angiotensin“aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF. Herz, 2016, 41, 76-86.	0.4	16
307	Potential New Agents for the Management of Hyperkalemia. American Journal of Cardiovascular Drugs, 2016, 16, 19-31.	1.0	16
308	Biosensor cell assay for measuring real-time aldosterone-induced release of histamine from mesenteric arteries. Acta Physiologica, 2017, 219, 219-226.	1.8	4

#	ARTICLE	IF	CITATIONS
309	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	107
310	Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists. <i>Journal for Nurse Practitioners</i> , 2017, 13, 156-161.	0.4	0
311	Short Stay Management of Acute Heart Failure. <i>Contemporary Cardiology</i> , 2017, , .	0.0	0
312	New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 1-6.	0.7	2
313	Heart Failure with Preserved Ejection Fraction: Diagnosis and Management. <i>American Journal of Medicine</i> , 2017, 130, 510-516.	0.6	33
314	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	79
315	Computer-aided assessment of the generalizability of clinical trial results. <i>International Journal of Medical Informatics</i> , 2017, 99, 60-66.	1.6	12
316	Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 399-409.	0.9	20
317	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	1.2	193
319	Renin-“Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	89
320	Heart Failure With Preserved Ejection Fraction: An Opportunity for Reflection. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	1
321	Spironolactone-“potion or poison?. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 13-13.	0.3	0
322	Potential Expanded Indications for Nephilysin Inhibitors. <i>Current Heart Failure Reports</i> , 2017, 14, 134-145.	1.3	26
323	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. <i>Current Hypertension Reports</i> , 2017, 19, 12.	1.5	38
324	Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1129-1142.	1.2	216
325	Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-“DHF pilot study. <i>ESC Heart Failure</i> , 2017, 4, 56-65.	1.4	21
326	“End-stage“™ heart failure therapy: potential lessons from congenital heart disease: from pulmonary artery banding and interatrial communication to parallel circulation. <i>Heart</i> , 2017, 103, 262-267.	1.2	26
327	Heart failure with preserved ejection fraction and skeletal muscle physiology. <i>Heart Failure Reviews</i> , 2017, 22, 141-148.	1.7	10

#	ARTICLE	IF	CITATIONS
328	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. <i>Current Heart Failure Reports</i> , 2017, 14, 59-70.	1.3	72
329	Towards Precision in HF Pharmacotherapy. <i>Current Heart Failure Reports</i> , 2017, 14, 1-6.	1.3	3
331	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 197-202.	1.3	17
332	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. <i>European Journal of Heart Failure</i> , 2017, 19, 974-986.	2.9	29
333	Validation of heart failure diagnosis registered in primary care records in two primary care centres in Barcelona (Spain) and factors related. A cross-sectional study. <i>European Journal of General Practice</i> , 2017, 23, 107-113.	0.9	12
334	Heart failure with preserved ejection fraction: a nephrologist-directed primer. <i>Heart Failure Reviews</i> , 2017, 22, 765-773.	1.7	14
335	Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1212-1219.	0.8	26
336	Epidemiology of heart failure with preserved ejection fraction. <i>Nature Reviews Cardiology</i> , 2017, 14, 591-602.	6.1	902
337	Heart Failure Guidelines on Pharmacotherapy. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 109-129.	0.9	8
338	Invasive Hemodynamic Assessment of Patients with Heart Failure and Pulmonary Hypertension. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 40.	0.4	3
339	Targets for Heart Failure With Preserved Ejection Fraction. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 228-237.	2.3	17
340	Example-based illustrations of design, conduct, analysis and result interpretation of multi-regional clinical trials. <i>Contemporary Clinical Trials</i> , 2017, 58, 13-22.	0.8	10
341	Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. <i>Clinical Cardiology</i> , 2017, 40, 692-696.	0.7	15
342	Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings. <i>Journal of Cardiac Failure</i> , 2017, 23, 517-524.	0.7	19
343	Efficient design of clinical trials and epidemiological research: is it possible?. <i>Nature Reviews Cardiology</i> , 2017, 14, 493-501.	6.1	34
344	Spironolactone Metabolites in TOPCAT " New Insights into Regional Variation. <i>New England Journal of Medicine</i> , 2017, 376, 1690-1692.	13.9	186
345	Heart failure. <i>Lancet, The</i> , 2017, 390, 1981-1995.	6.3	483
346	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 628-651.	0.7	531

#	ARTICLE	IF	CITATIONS
347	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , 2017, 136, e137-e161.	1.6	2,130
348	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 776-803.	1.2	2,256
349	Sex differences in cardiovascular disease – Impact on care and outcomes. <i>Frontiers in Neuroendocrinology</i> , 2017, 46, 46-70.	2.5	179
350	The Syndrome of Heart Failure With Preserved Systolic Function. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 232-233.	0.4	1
351	Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in <scp>TOPCAT</scp>. <i>European Journal of Heart Failure</i> , 2017, 19, 457-465.	2.9	14
352	Cardiac Fibrosis and Arrhythmogenesis. , 2017, 7, 1009-1049.		97
353	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	80
354	Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 233-244.	1.1	66
356	Management of heart failure in the elderly. <i>Current Opinion in Cardiology</i> , 2017, 32, 217-223.	0.8	10
357	30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor. <i>Journal of Endocrinology</i> , 2017, 234, T107-T124.	1.2	61
358	Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2374-2382.	1.3	36
359	Integrating electronic health records into the study of heart failure: promises and pitfalls. <i>European Journal of Heart Failure</i> , 2017, 19, 1128-1130.	2.9	8
360	Electrocardiographic Predictors of Heart Failure With Reduced Versus Preserved Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	44
362	Invited Commentary: Searching for the Perfect Measure of Diastolic Dysfunction – A Futile Exercise?. <i>American Journal of Epidemiology</i> , 2017, 185, 1228-1230.	1.6	1
363	Diagnosis and Management of Heart Failure in Older Adults. <i>Heart Failure Clinics</i> , 2017, 13, 427-444.	1.0	13
364	Heart Failure with Preserved Ejection Fraction in Older Adults. <i>Heart Failure Clinics</i> , 2017, 13, 485-502.	1.0	50
365	Monitoring renal safety in mineralocorticoid receptor antagonist trials. <i>European Journal of Heart Failure</i> , 2017, 19, 466-468.	2.9	2
366	Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2017, 119, 1785-1790.	0.7	32

#	ARTICLE	IF	CITATIONS
367	Diastolic dysfunction in hypertension. <i>Hipertension Y Riesgo Vascular</i> , 2017, 34, 128-139.	0.3	8
368	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1043-1052.	2.9	34
369	Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 283-298.	1.0	10
370	Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. <i>International Journal of Cardiology</i> , 2017, 238, 72-78.	0.8	22
371	Response to Endurance Exercise Training in Older Adults with Heart Failure with Preserved or Reduced Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1698-1704.	1.3	42
372	Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 30-39.	1.3	6
373	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 768-776.	0.8	11
374	New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 645-655.	0.9	12
375	Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 725-729.	0.5	17
376	Epigallocatechin gallate reverses α -low expression-induced age-related heart diastolic dysfunction through histone acetylation modification. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2481-2490.	1.6	24
377	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. <i>European Journal of Heart Failure</i> , 2017, 19, 1615-1623.	2.9	149
378	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	2.9	17
379	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 241-252.	1.9	129
380	Natriuretic Peptide Levels and Interaction With Treatment in HFpEF. <i>JACC: Heart Failure</i> , 2017, 5, 253-255.	1.9	0
381	Current Pharmacological Therapies in Heart Failure Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 107-114.	1.0	21
382	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. <i>American Heart Journal</i> , 2017, 188, 99-108.	1.2	55
383	The Effect of Trabeculae Carneae on Left Ventricular Diastolic Compliance: Improvement in Compliance With Trabecular Cutting. <i>Journal of Biomechanical Engineering</i> , 2017, 139, .	0.6	21
384	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	14

#	ARTICLE	IF	CITATIONS
385	Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	164
386	Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (<sc>TIMEâ€œCHF</sc>). <i>European Journal of Heart Failure</i> , 2017, 19, 1586-1596.	2.9	108
387	The heartâ€œkidney relationship in heart failure: it's not you, it's me. <i>European Journal of Heart Failure</i> , 2017, 19, 624-626.	2.9	0
388	Clinical characteristics and prognosis of patients admitted for heart failure: A 5-year retrospective study of African patients. <i>International Journal of Cardiology</i> , 2017, 238, 128-135.	0.8	34
389	Outcome Measures in HFrEF Trials. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1358-1359.	1.2	0
390	Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. <i>Clinical Research in Cardiology</i> , 2017, 106, 359-368.	1.5	57
391	Troponin Assessment in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 125.	3.0	0
392	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 92-98.	1.9	129
393	Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 2012-2018.	1.8	17
394	Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!. <i>European Journal of Heart Failure</i> , 2017, 19, 1086-1088.	2.9	6
395	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2017, 135, 724-735.	1.6	153
396	Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 1315.	3.0	126
397	A comprehensive populationâ€œbased characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1624-1634.	2.9	196
398	Heart Failure With Mid-Range (Borderline) Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 763-771.	1.9	141
399	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 782-791.	1.9	21
400	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2186-2200.	1.2	159
401	Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. <i>Circulation</i> , 2017, 136, 1548-1559.	1.6	172
402	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 1569-1573.	2.9	67

#	ARTICLE	IF	CITATIONS
403	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
404	A novel echocardiographic hemodynamic classification of heart failure based on stroke volume index and left atrial pressure. <i>Echocardiography</i> , 2017, 34, 1417-1425.	0.3	14
405	Geographical differences in the ratio of percutaneous and surgical myocardial revascularization procedures in the treatment of coronary artery disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 454-455.	0.6	3
406	Pharmacologic Management for Heart Failure and Emerging Therapies. <i>Current Cardiology Reports</i> , 2017, 19, 94.	1.3	9
407	The Initial Evaluation and Management of a Patient with Heart Failure. <i>Current Cardiology Reports</i> , 2017, 19, 103.	1.3	1
408	Atrial Fibrillation and Hypertension. <i>Hypertension</i> , 2017, 70, 854-861.	1.3	100
409	Heart Failure With Preserved Ejection Fraction: A Perioperative Review. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 1820-1830.	0.6	8
410	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	0.8	503
411	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 203-209.	1.3	3
412	Cardiac Amyloidosis as a Potential Confounder in Heart Failure With Preserved Ejection Fraction Trials. <i>JACC: Heart Failure</i> , 2017, 5, 617.	1.9	6
413	Relationships Between Periventricular Epicardial Adipose Tissue Accumulation, Coronary Microcirculation, and Left Ventricular Diastolic Dysfunction. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1489-1497.	0.8	42
414	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2017, 14, 434-443.	1.3	15
415	Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	81
416	A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function. <i>Scientific Reports</i> , 2017, 7, 16587.	1.6	34
417	Heart Failure and Sudden Cardiac Death. <i>Cardiac Electrophysiology Clinics</i> , 2017, 9, 709-723.	0.7	21
418	A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis. <i>Medicine (United States)</i> , 2017, 96, e8719.	0.4	16
419	Underutilization of Aldosterone Antagonists in Heart Failure. <i>Hospital Pharmacy</i> , 2017, 52, 698-703.	0.4	2
420	Abdominal Obesity Is Associated With Increased Risk of All-Cause Mortality in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2739-2749.	1.2	151

#	ARTICLE	IF	CITATIONS
421	Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2431-2440.	1.3	61
423	30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature. <i>Journal of Endocrinology</i> , 2017, 234, T67-T82.	1.2	72
424	Endothelial mineralocorticoid receptor contributes to systolic dysfunction induced by pressure overload without modulating cardiac hypertrophy or inflammation. <i>Physiological Reports</i> , 2017, 5, e13313.	0.7	25
425	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.	1.9	238
427	Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. <i>Heart Failure Reviews</i> , 2017, 22, 775-782.	1.7	27
428	Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 322-336.	1.1	41
429	Treatment of Hyperkalemia in Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 266-274.	1.3	16
430	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. <i>Current Heart Failure Reports</i> , 2017, 14, 217-222.	1.3	13
431	Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. <i>Cardiology</i> , 2017, 136, 192-203.	0.6	16
433	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. <i>International Journal of Cardiology</i> , 2017, 226, 65-70.	0.8	4
434	Ventricular-Arterial Coupling and Exercise-Induced Pulmonary Hypertension During Low-Level Exercise in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 216-220.	0.7	22
435	The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies. <i>International Journal of Cardiology</i> , 2017, 228, 4-10.	0.8	40
436	Long-term survival after acute myocardial infarction in patients with hypertrophic cardiomyopathy. <i>Clinical Cardiology</i> , 2017, 40, 26-31.	0.7	12
437	Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 48-57.	1.4	73
438	Deliberations on Diastolic Heart Failure. <i>American Journal of Cardiology</i> , 2017, 119, 138-144.	0.7	9
439	Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia. <i>Egyptian Heart Journal</i> , 2017, 69, 21-28.	0.4	7
440	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	0.7	35
441	Containing the Cost of Heart Failure Management. <i>Heart Failure Clinics</i> , 2017, 13, 21-28.	1.0	25

#	ARTICLE	IF	CITATIONS
442	Modes of death in patients with heart failure and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2017, 228, 422-426.	0.8	42
443	Heart Failure Stages Among Older Adults in the Community. <i>Circulation</i> , 2017, 135, 224-240.	1.6	135
444	Repeat Hospitalizations Predict Mortality in Patients With Heart Failure. <i>Military Medicine</i> , 2017, 182, e1932-e1937.	0.4	39
445	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. <i>The Cochrane Library</i> , 2017, , .	1.5	2
446	Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	32
447	Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	6
448	Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction—Prospective Randomized Controlled Study. <i>Circulation Journal</i> , 2017, 81, 740-747.	0.7	34
449	Aldosteronism in Congestive Heart Failure. , 2017, , 668-673.		0
450	Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure. , 0, , .		0
451	Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. <i>Yonago Acta Medica</i> , 2017, 60, 71-76.	0.3	9
452	Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots. <i>Current Vascular Pharmacology</i> , 2017, 16, 15-22.	0.8	24
453	Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. <i>Frontiers in Endocrinology</i> , 2017, 8, 160.	1.5	50
454	Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure—Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry. <i>Circulation Journal</i> , 2017, 81, 1662-1669.	0.7	9
456	Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF). <i>Korean Circulation Journal</i> , 2017, 47, 341.	0.7	131
457	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. <i>Korean Circulation Journal</i> , 2017, 47, 555.	0.7	56
458	Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-17.	1.9	43
459	Heart Failure with Preserved Ejection Fraction. , 0, , .		0
460	Interatrial shunt devices for heart failure with normal ejection fraction: a technology update. <i>Medical Devices: Evidence and Research</i> , 2017, Volume 10, 123-132.	0.4	2

#	ARTICLE	IF	CITATIONS
461	Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 359-366.	0.7	14
462	Echocardiographic Evaluation of Diastolic Function Is of Limited Value in the Diagnosis and Management of HFpEF. <i>Journal of Cardiac Failure</i> , 2018, 24, 392-396.	0.7	13
463	The role of angiotensin receptorâ€œneprilysin inhibitors in cardiovascular diseaseâ€œexisting evidence, knowledge gaps, and future directions. <i>European Journal of Heart Failure</i> , 2018, 20, 963-972.	2.9	35
464	Ejection fraction as a statistical index of left ventricular systolic function: the first full allometric scrutiny of its appropriateness and accuracy. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 976-985.	0.5	3
465	Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 Association, 2018, 7, .	1.6	25
466	The heart failure burden of type 2 diabetes mellitusâ€œa review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018, 23, 303-323.	1.7	41
467	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	2.9	434
468	Hypertension Management for the Prevention of Heart Failure: Best Strategies. <i>Current Cardiovascular Risk Reports</i> , 2018, 12, 1.	0.8	0
469	Atrial fibrillation and its pernicious role in heart failure with preserved ejection fraction: a new frontier in interventional electrophysiology. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 51, 89-90.	0.6	2
470	Derangements in adrenergicâ€œadipokine signalling establish a neurohormonal basis for obesityâ€œrelated heart failure with a preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 873-878.	2.9	34
471	Treatment of Heart Failure with Preserved Ejection Fraction. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1067, 67-87.	0.8	39
472	Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. <i>Canadian Journal of Cardiology</i> , 2018, 34, 632-643.	0.8	56
473	Heart failure and inhibition of renin-angiotensin-aldosterone system. <i>Cor Et Vasa</i> , 2018, 60, e263-e273.	0.1	2
474	Sudden Death in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 653-661.	1.9	56
475	Is galectin-3 a promoter of ventricular dysfunction?. <i>Romanian Journal of Laboratory Medicine</i> , 2018, 26, 21-36.	0.1	2
476	Influence of atrial fibrillation on the mortality of patients with heart failure with preserved ejection fraction. <i>Medicina ClÃnica (English Edition)</i> , 2018, 150, 376-382.	0.1	2
477	Geographic and racial representation and reported success rates of studies of catheter ablation for atrial fibrillation: Findings from the SMASHâ€œAF metaâ€œanalysis study cohort. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 747-755.	0.8	11
478	Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 263, 69-74.	0.8	39

#	ARTICLE	IF	CITATIONS
479	What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. <i>Current Cardiology Reports</i> , 2018, 20, 39.	1.3	27
480	Association between heart failure with preserved ejection fraction and hypertensive retinopathy: more questions than answers!. <i>Journal of Human Hypertension</i> , 2018, 32, 390-391.	1.0	0
481	B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 469-478.	1.6	25
482	The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?. <i>Heart Failure Reviews</i> , 2018, 23, 631-639.	1.7	26
483	Interatrial Shunting, a Novel Device-Based Therapy for Patients With Heart Failure. <i>Cardiology in Review</i> , 2018, 26, 267-273.	0.6	2
484	Novel Insights and Treatment Strategies for Right Heart Failure. <i>Current Heart Failure Reports</i> , 2018, 15, 141-155.	1.3	9
485	Heart Failure and Pulmonary Hypertension. , 2018, , 193-227.		1
486	Drug therapies in chronic heart failure: a focus on reduced ejection fraction. <i>Clinical Medicine</i> , 2018, 18, 138-145.	0.8	11
487	Leptin-Aldosterone-Nephrilysin Axis. <i>Circulation</i> , 2018, 137, 1614-1631.	1.6	163
488	Editorial commentary: Heart failure with preserved ejection fractionâ€”Clinical syndrome with incomplete understanding. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 401-402.	2.3	0
489	Sexâ€”Specific Mechanisms of Resistance Vessel Endothelial Dysfunction Induced by Cardiometabolic Risk Factors. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	64
490	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. <i>International Journal of Cardiology</i> , 2018, 254, 215-221.	0.8	19
491	Evaluation of an individualized dose titration regimen of patiomer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018, 5, 257-266.	1.4	50
492	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. <i>European Heart Journal</i> , 2018, 39, 1770-1780.	1.0	194
493	Low <sc>NTâ€”proBNP</sc> levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2018, 5, 372-378.	1.4	50
494	Heart Failure with Preserved Ejection Fraction. <i>Annual Review of Medicine</i> , 2018, 69, 65-79.	5.0	59
495	Pharmacological treatments for heart failure with preserved ejection fractionâ€”a systematic review and indirect comparison. <i>Heart Failure Reviews</i> , 2018, 23, 147-156.	1.7	33
496	Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selectionâ€”Focus on Group II Pulmonary Hypertension. <i>Current Heart Failure Reports</i> , 2018, 15, 81-93.	1.3	5

#	ARTICLE	IF	CITATIONS
497	Heart Failure. Primary Care - Clinics in Office Practice, 2018, 45, 63-79.	0.7	1
498	Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681775160.	0.6	23
499	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. Current Heart Failure Reports, 2018, 15, 10-16.	1.3	6
500	Gender-related differences in heart failure with preserved ejection fraction. Scientific Reports, 2018, 8, 1080.	1.6	60
501	Feasibility of optimizing pharmacotherapy in heart failure patients admitted to an acute geriatric ward: role of the clinical pharmacist. European Geriatric Medicine, 2018, 9, 103-111.	1.2	9
502	Obesity and heart failure with preserved ejection fraction: A growing problem. Trends in Cardiovascular Medicine, 2018, 28, 322-327.	2.3	17
503	Heart Failure With Preserved Ejection Fraction—A Systematic Review and Analysis of Perioperative Outcomes. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2423-2434.	0.6	5
504	Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM—HFpEF study. ESC Heart Failure, 2018, 5, 95-100.	1.4	31
505	Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care, 2018, 41, 11-13.	4.3	76
506	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND—HF. European Journal of Heart Failure, 2018, 20, 525-532.	2.9	29
507	Mineralocorticoid Receptor Antagonists Treatment in Resistant Hypertension and HFpEF: Evidence and Courage. American Journal of Hypertension, 2018, 31, 405-406.	1.0	0
508	Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. International Journal of Cardiology, 2018, 255, 111-117.	0.8	23
509	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. American Journal of Hypertension, 2018, 31, 407-414.	1.0	26
510	Sudden cardiac death following admission for acute heart failure: adding insult to injury. European Journal of Heart Failure, 2018, 20, 533-535.	2.9	3
511	The year in cardiology 2017: heart failure. European Heart Journal, 2018, 39, 832-839.	1.0	5
512	Recent advances in heart failure. Current Opinion in Cardiology, 2018, 33, 249-256.	0.8	15
513	Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart, 2018, 104, 377-384.	1.2	76
514	Comparison of Effects of Statin Use on Mortality in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2018, 122, 405-412.	0.7	19

#	ARTICLE	IF	CITATIONS
515	Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction – implications for clinical trials. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 4.	1.6	62
516	Chronic heart failure - Impact of the condition on patients and the healthcare system in the Czech Republic: A retrospective cost-of-illness analysis. <i>Cor Et Vasa</i> , 2018, 60, e224-e233.	0.1	4
517	Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1947-1957.	1.2	284
518	Heart failure with preserved ejection fraction. <i>Clinical Medicine</i> , 2018, 18, s24-s29.	0.8	23
519	Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. <i>American Journal of Medicine</i> , 2018, 131, 837-841.	0.6	50
520	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 597-607.	1.7	6
521	Combination Therapy of Renin Angiotensin System Inhibitors and β -Blockers in Patients with Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1067, 17-30.	0.8	7
522	Obesity-Related Heart Failure With a Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 633-639.	1.9	108
523	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 564-569.	1.9	43
524	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004457.	1.6	31
525	Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 28.	0.4	13
526	Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 1558-1566.	0.7	19
527	Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFREF: a report from the CHART-2 Study. <i>Heart and Vessels</i> , 2018, 33, 997-1007.	0.5	19
528	Role of Cardiac Magnetic Resonance in Heart Failure with Preserved Ejection Fraction. <i>Current Cardiovascular Imaging Reports</i> , 2018, 11, 1.	0.4	4
529	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320.	0.7	49
530	Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: Results from a randomized clinical trial. <i>Nutrition</i> , 2018, 54, 111-117.	1.1	24
531	The Current Focus of Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 321-329.	0.7	4
532	Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis. <i>Heart Failure Reviews</i> , 2018, 23, 547-553.	1.7	8

#	ARTICLE	IF	CITATIONS
533	Relationships between left ventricular sympathetic innervation and diastolic dysfunction: the role of myocardial innervation/perfusion mismatch. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 1101-1109.	1.4	21
534	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. <i>ESC Heart Failure</i> , 2018, 5, 19-26.	1.4	10
535	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	2.9	239
536	The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction. <i>Diabetes Care</i> , 2018, 41, 150-155.	4.3	88
537	Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 250, 195-200.	0.8	37
538	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. <i>Clinical Research in Cardiology</i> , 2018, 107, 214-221.	1.5	28
539	Benefit-Risk Assessment of Crataegus Extract WSÂ1442: An Evidence-Based Review. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 25-36.	1.0	34
540	Systemic Angiotensinogen Concentrations Are Independently Associated With Left Ventricular Diastolic Function in a Community Sample. <i>American Journal of Hypertension</i> , 2018, 31, 212-219.	1.0	3
541	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Heart Rhythm</i> , 2018, 15, e73-e189.	0.3	262
542	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2018, 138, e272-e391.	1.6	468
543	Influence of ejection fraction on causeâ€specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 815-816.	2.9	5
544	Heart failure with preserved ejection fraction: current management and future strategies. <i>Clinical Research in Cardiology</i> , 2018, 107, 1-19.	1.5	64
545	Effectiveness of a patient education programme in heart failure with preserved ejection fraction: Results from the ODIN cohort study using propensity score matching. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 5-16.	0.7	5
546	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensityâ€score matched study. <i>European Journal of Heart Failure</i> , 2018, 20, 345-354.	2.9	92
547	The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a subâ€analysis of the Jâ€MELODIC study. <i>ESC Heart Failure</i> , 2018, 5, 36-45.	1.4	17
548	Investigating a biomarkerâ€driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum Câ€terminal propeptide of procollagen type I (DROPâ€PIP trial). <i>European Journal of Heart Failure</i> , 2018, 20, 460-470.	2.9	29
549	Influencia de la fibrilaciÃn auricular en la mortalidad de los pacientes con insuficiencia cardiaca con fracciÃn de eyecciÃn preservada. <i>Medicina ClÃnica</i> , 2018, 150, 376-382.	0.3	13
550	Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , 2018, 36, 63-72.	0.9	12

#	ARTICLE	IF	CITATIONS
551	N -Terminal B-type Natriuretic Peptide in Heart Failure. <i>Heart Failure Clinics</i> , 2018, 14, 27-39.	1.0	45
552	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	2.9	52
553	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 483-490.	2.9	28
554	Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>Heart</i> , 2018, 104, 407-415.	1.2	107
555	Prognostic Value of ¹²³ I-BMIPP SPECT in Patients with Nonischemic Heart Failure with Preserved Ejection Fraction. <i>Journal of Nuclear Medicine</i> , 2018, 59, 259-265.	2.8	15
556	Guideline-Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient-Pooled Analysis From the KorHF and KorAHF Registries. <i>Journal of the American Heart Association</i> , 2018, 7, e009806.	1.6	25
557	A new educational program in heart failure drug development. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 411-421.	0.6	8
558	Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 799-805.	0.6	13
559	Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction. <i>Medicine (United States)</i> , 2018, 97, e13690.	0.4	4
561	Hartfalen en COPD. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2018, 34, 448-455.	0.0	0
562	OBSOLETE: Ventricular Remodeling in Heart Failure. , 2018, , .		0
563	OBSOLETE: Heart Failure With Preserved Ejection Fraction. , 2018, , .		0
564	OBSOLETE: Practical Guide to Evidence-Based Management of Heart Failure in the Outpatient Setting. , 2018, , .		0
565	OBSOLETE: Management and Care of Older Cardiac Patients. , 2018, , .		0
566	OBSOLETE: Neurohormonal Blockade. , 2018, , .		0
567	¹⁸ F-Labeled Derivatives of Irbesartan for Angiotensin-II Receptor PET Imaging. <i>ChemMedChem</i> , 2018, 13, 2546-2557.	1.6	9
568	Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 875-877.	0.6	1
569	The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 351-359.	1.0	6

#	ARTICLE	IF	CITATIONS
570	Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 975-982.	1.9	111
571	Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005312.	1.6	43
572	Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity. Therapeutic Innovation and Regulatory Science, 2018, , 216847901880542.	0.8	1
573	Ventricular Remodeling in Heart Failure. , 2018, , 683-689.		1
574	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005288.	1.6	35
575	How to Increase Your "Power": Hip and Pelvis, 2018, 30, 1-4.	0.6	0
576	Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2018, 14, 525-535.	1.0	9
577	Imaging and Management of Heart Failure and Preserved Ejection Fraction. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 90.	0.4	8
578	Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.9	73
579	Targeted HFpEF therapy based on matchmaking of human and animal models. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H1670-H1683.	1.5	16
580	Treatment of heart failure with preserved ejection fraction. Monaldi Archives for Chest Disease, 2018, 88, 951.	0.3	0
581	Frailty in TOPCAT: a deep dive into the deficit index approach for defining frailty. European Journal of Heart Failure, 2018, 20, 1578-1579.	2.9	3
582	Clinical Characteristics and Outcomes in the Very Elderly Patients Hospitalized for Acute Heart Failure: Importance of Pharmacologic Guideline Adherence. Scientific Reports, 2018, 8, 14270.	1.6	10
583	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004783.	0.9	13
584	Improving Postdischarge Outcomes in Acute Heart Failure. American Journal of Therapeutics, 2018, 25, e475-e486.	0.5	17
585	Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial. Journal of the American Heart Association, 2018, 7, e009664.	1.6	16
586	Practical Guide to Evidence-Based Management of Heart Failure in the Outpatient Setting. , 2018, , 125-142.		0
587	Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-10.	1.9	46

#	ARTICLE	IF	CITATIONS
588	What's new in heart failure therapy 2018? Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 921-930.	0.5	8
590	Impact of the duration of the evidence-based medicine use in acute heart failure: A nationwide cohort study. PLoS ONE, 2018, 13, e0205440.	1.1	0
591	Redefining heart failure phenotypes based on ejection fraction. European Journal of Heart Failure, 2018, 20, 1634-1635.	2.9	9
592	What is Heart Failure with Mid-range Ejection Fraction? A New Subgroup of Patients with Heart Failure. Cardiac Failure Review, 2018, 4, 1.	1.2	13
593	Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009594.	1.6	87
595	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine, 2018, 379, 986-987.	13.9	35
596	Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves. Cardiovascular Drugs and Therapy, 2018, 32, 577-580.	1.3	1
597	Mineralocorticoid Receptor and Cardiovascular Disease. American Journal of Hypertension, 2018, 31, 1165-1174.	1.0	80
598	The frailty syndrome and outcomes in the TOPCAT trial. European Journal of Heart Failure, 2018, 20, 1570-1577.	2.9	106
599	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics, 2018, 36, 1463-1473.	1.7	14
600	Effects of spironolactone in heart failure with preserved ejection fraction. Medicine (United States), 2018, 97, e11942.	0.4	14
601	Politically Correct Heart Failure Research in America to Avoid Geographic Variation. JACC: Heart Failure, 2018, 6, 805-806.	1.9	0
602	Limited Impact of Î²-Adrenergic Receptor Activation on Left Ventricular Diastolic Function in Rat Models of Hypertensive Heart Disease. Journal of Cardiovascular Pharmacology, 2018, 72, 242-251.	0.8	0
603	Right Ventricular Dysfunction and Long-Term Risk of Sudden Cardiac Death in Patients With and Without Severe Left Ventricular Dysfunction. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006091.	2.1	34
604	Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction. Autonomic Neuroscience: Basic and Clinical, 2018, 213, 8-14.	1.4	15
605	Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. European Journal of Preventive Cardiology, 2018, 25, 1268-1277.	0.8	14
606	Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction. European Journal of Heart Failure, 2018, 20, 1240-1242.	2.9	3
607	Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings. European Journal of Heart Failure, 2018, 20, 1300-1302.	2.9	4

#	ARTICLE	IF	CITATIONS
608	Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction. <i>International Journal of Cardiology</i> , 2018, 268, 166-169.	0.8	4
609	Progress in heart failure treatment in Germany. <i>Clinical Research in Cardiology</i> , 2018, 107, 105-113.	1.5	9
610	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. <i>The Cochrane Library</i> , 2018, 6, CD012721.	1.5	56
611	Heart failure with preserved ejection fraction: A systemic disease linked to multiple comorbidities, targeting new therapeutic options. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 766-781.	0.7	26
612	Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction. <i>Scientific Reports</i> , 2018, 8, 9556.	1.6	23
613	Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 41-44.	1.2	1
614	Heart failure with mid-range ejection fraction and with preserved ejection fraction. <i>Herz</i> , 2018, 43, 392-405.	0.4	6
615	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	1.4	29
616	Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. <i>European Journal of Heart Failure</i> , 2018, 20, 1436-1443.	2.9	31
617	Aldosterone and Its Cardiovascular Effects. , 2018, , 451-463.		0
618	Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines. <i>ESC Heart Failure</i> , 2018, 5, 745-754.	1.4	36
619	Heart Failure. <i>Annals of Internal Medicine</i> , 2018, 168, ITC81-ITC96.	2.0	11
620	Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.	1.9	103
621	HFpEF. <i>JACC: Heart Failure</i> , 2018, 6, 718-719.	1.9	8
622	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. <i>European Heart Journal</i> , 2018, 39, 3417-3438.	1.0	42
623	Renin Angiotensin Aldosterone System Blockers. , 2018, , 230-241.		1
624	Sex Differences in Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1065, 529-544.	0.8	43
625	Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. <i>JAMA Cardiology</i> , 2018, 3, 883.	3.0	8

#	ARTICLE	IF	CITATIONS
626	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. <i>Medical Journal of Australia</i> , 2018, 209, 363-369.	0.8	31
627	Primary and Secondary Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 1578-1587.	0.7	37
628	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. <i>Heart Lung and Circulation</i> , 2018, 27, 1123-1208.	0.2	262
629	Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides?. <i>Journal of Animal Science and Technology</i> , 2018, 5, R65-R75.	0.8	21
630	Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. <i>Archives of Medical Science</i> , 2018, 14, 890-909.	0.4	42
631	Heart Failure With Preserved Ejection Fraction. , 2018, , 464-468.		1
632	Heart Failure With Preserved Ejection Fraction. , 2018, , 209-215.		0
633	Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 121, 124-133.	0.9	32
634	Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 579-589.	0.6	38
635	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
636	Serum Potassium and Cardiovascular Events in Heart Failure With Preserved Left Ventricular Ejection Fraction Patients. <i>American Journal of Hypertension</i> , 2018, 31, 1098-1105.	1.0	22
637	Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	4
638	CSI position statement on management of heart failure in India. <i>Indian Heart Journal</i> , 2018, 70, S1-S72.	0.2	18
639	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 689-697.	1.9	68
640	Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 53, 9-17.	0.6	2
641	A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1263-1267.	0.8	2
642	Development and validation of a heart failure with preserved ejection fraction cohort using electronic medical records. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 128.	0.7	29
643	Ventricular Arrhythmias Underlie Sudden Death in Rats With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006452.	2.1	33

#	ARTICLE	IF	CITATIONS
644	Effect of Cigarette Smoking on Risk for Adverse Events in Patients With Heart Failure and Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 400-404.	0.7	4
645	HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers. <i>Current HIV/AIDS Reports</i> , 2018, 15, 233-244.	1.1	38
646	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
647	Neurohormonal Blockade. , 2018, , 459-476.		0
648	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Journal of the American College of Cardiology</i> , 2018, 72, e91-e220.	1.2	991
649	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1000.	3.0	41
650	Skeletal Muscle Pump Function Is Associated With Exercise Capacity in Patients With Heart Failure. <i>Circulation Journal</i> , 2018, 82, 1033-1040.	0.7	13
651	Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. <i>Heart Failure Reviews</i> , 2018, 23, 609-629.	1.7	29
652	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018, 39, 2780-2792.	1.0	250
653	Prognostic Significance of Baseline Serum Sodium in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	23
654	Role of Aldosterone Receptor Antagonists in Heart Failure With Preserved Ejection Fraction. <i>Clinical Medicine Insights Therapeutics</i> , 2018, 10, 1179559X1877135.	0.4	1
655	Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1247-1251.	2.9	17
656	Heart failure and co-morbidity revisited; the elephant in the room. <i>European Journal of Heart Failure</i> , 2018, 20, 1267-1268.	2.9	4
657	Entrenamiento de la musculatura inspiratoria y la electroestimulación muscular funcional en el tratamiento de la insuficiencia cardiaca con función sistólica conservada: estudio TRAINING-HF. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 288-297.	0.6	23
658	Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2019, 56, 2559-2578.	1.9	2
659	Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease. <i>Journal of Cellular Physiology</i> , 2019, 234, 2252-2265.	2.0	80
660	Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1564-1578.	1.2	27
661	Benefit-risk review of different drug classes used in chronic heart failure. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 37-49.	1.0	10

#	ARTICLE	IF	CITATIONS
662	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019, 21, 23-36.	2.9	102
663	Angiotensin receptor neprilysin inhibitors in older patients with heart failure. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 5-7.	1.7	2
664	Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2019, 98, e14967.	0.4	25
665	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019, 7, 913-921.	1.9	6
666	Mineralocorticoid antagonists in the treatment of central serous chorioetiniopathy: Review of the pre-clinical and clinical evidence. <i>Experimental Eye Research</i> , 2019, 187, 107754.	1.2	25
667	Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model. <i>PLoS ONE</i> , 2019, 14, e0220837.	1.1	22
669	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). <i>Hypertension Research</i> , 2019, 42, 1235-1481.	1.5	1,047
670	Hypertensive Heart Failure in the Very Old. <i>Heart Failure Clinics</i> , 2019, 15, 477-485.	1.0	11
671	Heart Failure in Women Due to Hypertensive Heart Disease. <i>Heart Failure Clinics</i> , 2019, 15, 497-507.	1.0	4
672	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 664-675.	1.9	68
673	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	1.9	77
674	Clinical Characteristics and Long-Term Outcomes of Patients with Acute Decompensated Heart Failure with Mid-Range Ejection Fraction. <i>International Heart Journal</i> , 2019, 60, 862-869.	0.5	7
675	Application of the H ₂ FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1288-1291.	2.9	18
676	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 683-698.	1.2	22
677	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	1.2	97
678	Impact of Sex on Ventricular Vascular Stiffness and Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy. <i>Journal of the American Heart Association</i> , 2019, 8, e012190.	1.6	18
679	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	2.9	52
680	Use of Nitrates and Risk of Cardiovascular Events in Patients With Heart Failure With Preserved Ejection Fraction. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1210-1220.	1.4	10

#	ARTICLE	IF	CITATIONS
681	The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease. , 2019, 203, 107387.		26
682	Clinical and Socioeconomic Predictors of Heart Failure Readmissions: A Review of Contemporary Literature. Mayo Clinic Proceedings, 2019, 94, 1304-1320.	1.4	32
683	Lumpers and splitters: the bumpy road to precision medicine. European Heart Journal, 2019, 40, 3292-3296.	1.0	15
684	Large Magnetoresistance in an Electric-Field-Controlled Antiferromagnetic Tunnel Junction. Physical Review Applied, 2019, 12, .	1.5	8
685	Risk factor-based subphenotyping of heart failure in the community. PLoS ONE, 2019, 14, e0222886.	1.1	8
686	Long-term Prognostic Value of Estimated Plasma Volume in Heart Failure with Preserved Ejection Fraction. Scientific Reports, 2019, 9, 14369.	1.6	19
687	Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?. Current Hypertension Reports, 2019, 21, 86.	1.5	17
688	The Evolution from Hypertension to Heart Failure. Heart Failure Clinics, 2019, 15, 447-453.	1.0	35
689	SGLTâ€2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. Journal of the American Heart Association, 2019, 8, e013389.	1.6	119
690	PARAGON-HF â€” Why We Do Randomized, Controlled Clinical Trials. New England Journal of Medicine, 2019, 381, 1675-1676.	13.9	12
691	Myocardial Strain for Identification of Î²-Blocker Responders in Heart Failure with Preserved Ejection Fraction. Journal of the American Society of Echocardiography, 2019, 32, 1462-1469.e8.	1.2	22
692	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). American Journal of Cardiology, 2019, 124, 1912-1917.	0.7	13
693	20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicineâ€”Digital Biopsy to Deconstruct Biology. Journal of the American Society of Echocardiography, 2019, 32, 1379-1395.e2.	1.2	15
694	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2019, 10, 1347.	1.3	81
695	Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2019, 6, 143.	1.1	16
696	Dilated Cardiomyopathy With Midâ€Range Ejection Fraction at Diagnosis: Characterization and Natural History. Journal of the American Heart Association, 2019, 8, e010705.	1.6	9
697	Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986837.	1.1	2
698	Angiotensinâ€Nepirylsin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	13.9	1,485

#	ARTICLE	IF	CITATIONS
699	Heart Failure with Preserved Ejection Fraction. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 184-188.	0.6	1
700	Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging. <i>Frontiers in Endocrinology</i> , 2019, 10, 584.	1.5	53
701	Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets. <i>Frontiers in Physiology</i> , 2019, 10, 1108.	1.3	49
702	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	1.2	4
703	Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. <i>JACC Basic To Translational Science</i> , 2019, 4, 575-591.	1.9	125
704	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e030596.	0.8	12
705	The PARAGON-Heart failure trial – another disappointment for heart failure patients with hypertension and preserved ejection fraction. <i>Blood Pressure</i> , 2019, 28, 276-278.	0.7	0
706	Aldosterone, the Mineralocorticoid Receptor and Mechanisms of Cardiovascular Disease. <i>Vitamins and Hormones</i> , 2019, 109, 361-385.	0.7	9
707	Artificial Intelligence Transforms the Future of Health Care. <i>American Journal of Medicine</i> , 2019, 132, 795-801.	0.6	255
708	Hyponatremia at discharge is associated with adverse prognosis in acute heart failure syndromes with preserved ejection fraction: a report from the JASPER registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 623-633.	0.4	8
709	Different Impact of Changes in Left Ventricular Ejection Fraction Between Heart Failure Classifications in Patients With Acute Decompensated Heart Failure. <i>Circulation Journal</i> , 2019, 83, 584-594.	0.7	13
710	Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e801-e813.	1.6	37
711	Aldosterone and Myocardial Pathology. <i>Vitamins and Hormones</i> , 2019, 109, 387-406.	0.7	6
712	Myocardial Strain and Dyssynchrony. <i>Heart Failure Clinics</i> , 2019, 15, 167-178.	1.0	3
713	Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT. <i>European Journal of Heart Failure</i> , 2019, 21, 634-642.	2.9	42
714	Obesity-related heart failure with preserved ejection fraction: new treatment strategies. <i>Hospital Practice (1995)</i> , 2019, 47, 67-72.	0.5	7
715	Osteopontin in HFpEF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2719-2721.	1.2	1
716	ACC/AHA Versus ESC Guidelines on Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2756-2768.	1.2	195

#	ARTICLE	IF	CITATIONS
717	The Partial Adenosine A1 receptor agonist in patients with Chronic Heart failure and preserved Ejection fraction (PANACHE) trial. <i>Cardiovascular Research</i> , 2019, 115, e71-e73.	1.8	4
718	Association of Mineralocorticoid Receptor Antagonist Use With All-Cause Mortality and Hospital Readmission in Older Adults With Acute Decompensated Heart Failure. <i>JAMA Network Open</i> , 2019, 2, e195892.	2.8	48
719	Trabecular cutting: a novel surgical therapy to increase diastolic compliance. <i>Journal of Applied Physiology</i> , 2019, 127, 457-463.	1.2	1
721	Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction. <i>Hypertension</i> , 2019, 74, 285-294.	1.3	26
722	Discovery of biomarkers for the presence and progression of left ventricular diastolic dysfunction and HEart faiLure with Preserved ejection Fraction in patients at risk for cardiovascular disease: rationale and design of the HELPFul case-cohort study in a Dutch cardiology outpatient clinic. <i>BMJ Open</i> , 2019, 9, e028408.	0.8	8
723	Cardiorenal syndrome in heart failure with preserved ejection fraction—“an under-recognized clinical entity. <i>Heart Failure Reviews</i> , 2019, 24, 421-437.	1.7	26
724	Pulmonary Hypertension Due to Left Heart Disease: an Update. <i>Current Cardiology Reports</i> , 2019, 21, 62.	1.3	13
725	Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions. <i>Circulation</i> , 2019, 140, 353-365.	1.6	95
726	Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target. <i>Heart Failure Reviews</i> , 2019, 24, 847-866.	1.7	25
727	Ethnic differences in acute heart failure outcomes in Ontario. <i>International Journal of Cardiology</i> , 2019, 291, 177-182.	0.8	9
728	Home-based inspiratory muscle training for management of older patients with heart failure with preserved ejection fraction: does baseline inspiratory muscle pressure matter?. <i>European Journal of Cardiovascular Nursing</i> , 2019, 18, 621-627.	0.4	9
729	Exercise in Heart Failure—“What Is the Optimal Dose to Improve Pathophysiology and Exercise Capacity?. <i>Current Heart Failure Reports</i> , 2019, 16, 98-107.	1.3	16
730	The PARAGON Heart Failure trial —“ ongoing investigation of the angiotensin receptor antagonist/nephrilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. <i>Blood Pressure</i> , 2019, 28, 215-216.	0.7	3
731	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. <i>Circulation Research</i> , 2019, 124, 1520-1535.	2.0	115
732	Medical Therapy for Heart Failure Associated With Pulmonary Hypertension. <i>Circulation Research</i> , 2019, 124, 1551-1567.	2.0	45
733	Heart Failure With Preserved Ejection Fraction In Perspective. <i>Circulation Research</i> , 2019, 124, 1598-1617.	2.0	500
734	Green tea extract catechin improves cardiac function in pediatric cardiomyopathy patients with diastolic dysfunction. <i>Journal of Biomedical Science</i> , 2019, 26, 32.	2.6	18
735	Pirfenidone in Heart Failure with Preserved Ejection Fraction—“Rationale and Design of the PIRQUETTE Trial. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 461-470.	1.3	48

#	ARTICLE	IF	CITATIONS
737	Diastolic Function Gets Personal. JACC: Cardiovascular Imaging, 2019, 12, 950-952.	2.3	1
738	Inflammatory and Molecular Pathways in Heart Failure—Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. International Journal of Molecular Sciences, 2019, 20, 2322.	1.8	61
739	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 418-427.	1.9	20
740	Atrial Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 2465-2476.	1.2	218
741	Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Failure Reviews, 2019, 24, 535-547.	1.7	92
742	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	2.6	232
743	Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center. Pharmacy Practice, 2019, 17, 1376.	0.8	1
744	Influence Motivation of Entrepreneurs, Self-Efficacy, Skills Heritage, Attitude and Personality against Interest of Business. SSRN Electronic Journal, 2019, , .	0.4	0
745	HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases. International Journal of Molecular Sciences, 2019, 20, 1329.	1.8	74
746	Serial sodium values and adverse outcomes in heart failure with preserved ejection fraction. International Journal of Cardiology, 2019, 290, 119-124.	0.8	4
747	Cardiac fibrosis: potential therapeutic targets. Translational Research, 2019, 209, 121-137.	2.2	118
748	The Impact of Physiological Factors on 30-day Unplanned Rehospitalization in Adults with Heart Failure. Journal of Community Health Nursing, 2019, 36, 31-41.	0.1	1
749	Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries and Therapeutics, 2019, 13, 38-46.	0.6	25
750	Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 325-331.	0.6	7
751	Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure – A danish nationwide registry-based study. European Journal of Internal Medicine, 2019, 63, 56-61.	1.0	20
752	Heart failure drug treatment. Lancet, The, 2019, 393, 1034-1044.	6.3	233
753	Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet, The, 2019, 393, 1045-1055.	6.3	48
754	New frontiers for management of hyperkalaemia: the emergence of novel agents. European Heart Journal Supplements, 2019, 21, A34-A40.	0.0	3

#	ARTICLE	IF	CITATIONS
755	A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 129, 257-265.	0.9	15
756	Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 837-847.	0.8	6
757	Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e011077.	1.6	61
758	Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry. <i>Korean Circulation Journal</i> , 2019, 49, 238.	0.7	12
759	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019, 12, e005766.	1.6	21
760	Detecting Anomalies Among Practice Sites Within Multicenter Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004907.	0.9	2
761	Generalizability and Implications of the H ₂ FPEF Score in a Cohort of Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019, 139, 1851-1853.	1.6	32
762	Evaluation of Pharmacist Impact Within an Interdisciplinary Inpatient Heart Failure Consult Service. <i>Annals of Pharmacotherapy</i> , 2019, 53, 905-915.	0.9	4
763	Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 20.	0.4	30
764	Hypertension and Heart Failure. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , .	0.1	0
765	The Role of Drug Therapy in Lowering Mortality and Morbidity: From Established Heart Failure to High-Risk Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 245-260.	0.1	0
766	New Drugs for the Hypertensive Failing Heart. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 313-334.	0.1	0
767	Heart Failure with Preserved Ejection Fraction: Time to Revisit the Stiff Heart. <i>Cardiovascular Innovations and Applications</i> , 2019, 3, .	0.1	1
768	Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 693-695.	2.9	3
769	Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>Hypertension Research</i> , 2019, 42, 504-513.	1.5	15
770	Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome?. <i>JACC: Heart Failure</i> , 2019, 7, 192-203.	1.9	46
771	Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 228-238.	1.9	123
772	Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology. <i>JACC: Heart Failure</i> , 2019, 7, 239-249.	1.9	82

#	ARTICLE	IF	CITATIONS
773	Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. <i>Cardiovascular Medicine</i> , 2019, , 105-120.	0.0	0
774	Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19
775	The renin-angiotensin-aldosterone system and its suppression. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 363-382.	0.6	251
776	Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 1-13.	1.2	68
777	Hyperkalaemia: aetiology, epidemiology, and clinical significance. <i>European Heart Journal Supplements</i> , 2019, 21, A6-A11.	0.0	23
778	Beta-Blockers in Heart Failure with Preserved Ejection Fraction: Could Their Use Be Vindicated as an Acceptable Option in the Future Treatment Guideline?. <i>Korean Circulation Journal</i> , 2019, 49, 249.	0.7	4
779	Left Ventricular Size and Ejection Fraction. <i>Heart Failure Clinics</i> , 2019, 15, 147-158.	1.0	5
780	ST2 in heart failure with preserved and reduced ejection fraction. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 21-27.	0.4	40
783	Decelerating trends in heart failure survival. <i>European Journal of Heart Failure</i> , 2019, 21, 1326-1328.	2.9	1
784	Renin-angiotensin-aldosterone system and kidney interactions in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2019, 20, 147032031988941.	1.0	6
785	Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2019, 98, e17069.	0.4	17
786	Managing hypertension in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 359-366.	0.8	6
787	Clinical Implications of the New York Heart Association Classification. <i>Journal of the American Heart Association</i> , 2019, 8, e014240.	1.6	133
788	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2858-2873.	1.2	138
789	MRAs in Elderly HF Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1012-1021.	1.9	33
790	Influence of Age on Efficacy and Safety of Spirolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	1.9	6
791	Age-Related Divergence of Risk-Benefit Relationship of Spirolactone Treatment for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 1029-1031.	1.9	0
792	Tailoring treatment of hyperkalemia. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, iii62-iii68.	0.4	3

#	ARTICLE	IF	CITATIONS
793	Association of β -Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction. <i>JAMA Network Open</i> , 2019, 2, e1916598.	2.8	94
794	Is PARAGON a Paragon Example of an HFpEF Clinical Trial?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2874-2877.	1.2	1
795	Sirtuin 3, Endothelial Metabolic Reprogramming, and Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 315-323.	0.8	31
796	Limited contribution of left ventricular mass and remodelling to the impact of blood pressure on diastolic function in a community sample. <i>Journal of Hypertension</i> , 2019, 37, 1191-1199.	0.3	10
797	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure—Digest Version. <i>Circulation Journal</i> , 2019, 83, 2084-2184.	0.7	446
798	Effects of blood pressure-lowering drugs in heart failure. <i>Journal of Hypertension</i> , 2019, 37, 1757-1767.	0.3	7
799	Updates in the management of heart failure for the chronic kidney disease patient. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 262-266.	1.0	6
800	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	1.6	78
801	Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 571-579.	1.0	7
802	Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. <i>Heart and Vessels</i> , 2019, 34, 279-289.	0.5	10
803	Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction. <i>Current Medical Research and Opinion</i> , 2019, 35, 561-568.	0.9	7
804	Insulin resistance influences the impact of hypertension on left ventricular diastolic dysfunction in a community sample. <i>Clinical Cardiology</i> , 2019, 42, 305-311.	0.7	10
805	New drugs in preclinical and early stage clinical development in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 51-71.	1.9	15
806	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 65-76.	1.9	62
807	The Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 795-797.	2.3	0
808	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019, 7, 25-32.	1.9	51
809	Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1385-1406.	2.9	15
810	Vive les Differences! A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?. <i>International Journal of Clinical Practice</i> , 2019, 73, e13307.	0.8	0

#	ARTICLE	IF	CITATIONS
811	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
812	Canrenone on cardiovascular mortality in congestive heart failure. <i>Pharmacological Research</i> , 2019, 141, 46-52.	3.1	4
813	Opportunistic screening models for high-risk men and women to detect diastolic dysfunction and heart failure with preserved ejection fraction in the community. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 613-623.	0.8	16
814	Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease—Report From the JASPER Study. <i>Circulation Journal</i> , 2019, 83, 357-367.	0.7	24
815	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney International</i> , 2019, 95, 973-982.	2.6	70
816	Right Ventricular Pulmonary Coupling as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction. <i>Circulation Research</i> , 2019, 124, 186-188.	2.0	0
817	Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2019, 24, 367-377.	1.7	23
818	Student pharmacists' performance and perceptions on an evidence-based medicine objective structured clinical examination. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 302-308.	0.4	7
819	High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 177-186.	1.2	37
820	15-Year Trends in Patients Hospitalised With Heart Failure and Enrolled in an Australian Heart Failure Management Program. <i>Heart Lung and Circulation</i> , 2019, 28, 1646-1654.	0.2	11
821	The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. <i>International Journal of Cardiology</i> , 2019, 284, 42-49.	0.8	19
822	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 62-69.	1.4	45
823	Heart failure in the outpatient versus inpatient setting: findings from the BIostat CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 112-120.	2.9	44
824	Contemporary Management of Heart Failure in the Elderly. <i>Drugs and Aging</i> , 2019, 36, 137-146.	1.3	8
825	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin in Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	0.7	21
826	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 41-63.	4.2	23
827	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 288-297.	0.4	12
828	Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 784-794.	2.3	22

#	ARTICLE	IF	CITATIONS
829	Heart Failure With Preserved Ejection Fraction: Prevention and Management. <i>American Journal of Lifestyle Medicine</i> , 2019, 13, 182-189.	0.8	16
830	Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial. <i>Journal of Telemedicine and Telecare</i> , 2020, 26, 64-72.	1.4	38
831	Prognostic values of 123I-MIBG myocardial scintigraphy and heart rate variability in patients with heart failure with preserved ejection fraction. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 833-842.	1.4	7
832	Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 73-80.	1.0	32
833	Chronic kidney disease, heart failure and neprilysin inhibition. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 558-564.	0.4	39
834	ALDH2 rs671 polymorphism and the risk of heart failure with preserved ejection fraction (HFpEF) in patients with cardiovascular diseases. <i>Journal of Human Hypertension</i> , 2020, 34, 16-23.	1.0	19
835	Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 12-21.	1.9	152
836	Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 101-110.	0.7	35
837	Treatment of Heart Failure with Preserved Ejection Fraction. , 2020, , 568-585.		0
838	Alterations in Ventricular Function. , 2020, , 151-165.e3.		0
839	Heart Failure as a Consequence of Hypertension. , 2020, , 333-346.e6.		0
841	Characteristics and outcomes of HFpEF with declining ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 225-234.	1.5	20
842	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. <i>Heart Failure Reviews</i> , 2020, 25, 31-42.	1.7	52
844	Sex and Gender-Related Issues in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 121-130.	1.0	13
845	New horizons in management of heart failure in older patients. <i>Age and Ageing</i> , 2020, 49, 16-19.	0.7	5
846	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2020, 22, 557-559.	2.9	5
847	Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2020, 10, 32-41.	0.7	4
848	Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study. <i>Clinical and Translational Science</i> , 2020, 13, 275-283.	1.5	18

#	ARTICLE	IF	CITATIONS
849	Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 148-158.	2.9	169
850	Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 172-184.	1.9	208
851	Imaging of Diastolic Dysfunction in Community-Based Epidemiological Studies and Randomized Controlled Trials of HFpEF. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 310-326.	2.3	18
852	Heart Failure With Mid-range Ejection Fraction. <i>Current Heart Failure Reports</i> , 2020, 17, 1-8.	1.3	24
853	Heart failure with preserved ejection fraction: Similarities and differences between women and men. <i>International Journal of Cardiology</i> , 2020, 304, 101-108.	0.8	18
854	Restoration of myocellular copper-trafficking proteins and mitochondrial copper enzymes repairs cardiac function in rats with diabetes-evoked heart failure. <i>Metallomics</i> , 2020, 12, 259-272.	1.0	20
855	Heart failure with preserved ejection fraction: New approaches to diagnosis and management. <i>Clinical Cardiology</i> , 2020, 43, 145-155.	0.7	83
856	Heart failure with reduced and preserved ejection fraction in adult congenital heart disease. <i>Heart Failure Reviews</i> , 2020, 25, 569-581.	1.7	16
857	Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 1127-1146.e1.	0.6	5
858	Body mass index and all-cause readmissions following acute heart failure hospitalization. <i>International Journal of Obesity</i> , 2020, 44, 1227-1235.	1.6	10
859	Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). <i>Journal of the American College of Cardiology</i> , 2020, 75, 1077-1086.	0.7	27
860	Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial). <i>American Journal of Cardiology</i> , 2020, 125, 82-86.	0.7	2
862	Precision medicine at the academic-industry interface. <i>Journal of the American College of Cardiology</i> , 2020, 75, 545-560.		1
863	Sudden cardiac death risk prediction in heart failure with preserved ejection fraction. <i>Heart Rhythm</i> , 2020, 17, 358-364.	0.3	31
864	Medical Therapies for Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2020, 75, 23-32.	1.3	61
865	It is time for consistency in the use of biomarkers in heart failure clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 90-91.	2.9	2
866	Contemporary approach to treating heart failure. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 507-518.	2.3	9
867	Sudden Arrhythmic Death at the Higher End of the Heart Failure Spectrum. <i>Angiology</i> , 2020, 71, 389-396.	0.8	3

#	ARTICLE	IF	CITATIONS
868	¿Hay evidencia para el bloqueo neurohormonal en pacientes con insuficiencia cardiaca y fracción de eyección conservada?. REC: CardioClinics, 2020, 55, 128-130.	0.1	0
869	Pulmonary hypertension associated with left-sided heart failure. Current Opinion in Cardiology, 2020, 35, 610-619.	0.8	13
870	Endothelial dysfunction and the risk of heart failure in a community-based study: the Multi-Ethnic Study of Atherosclerosis. ESC Heart Failure, 2020, 7, 4231-4240.	1.4	13
871	Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial. ESC Heart Failure, 2020, 7, 4478-4487.	1.4	15
872	The PARAGON-HF Trial. JACC: Heart Failure, 2020, 8, 697-698.	1.9	2
873	Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction. BMJ Open, 2020, 10, e038294.	0.8	32
874	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	2.9	23
875	Interatrial shunt devices for the treatment of heart failure. Trends in Cardiovascular Medicine, 2020, 31, 427-432.	2.3	10
876	The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction. International Journal of Cardiology, 2020, 321, 12-17.	0.8	9
877	Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure. American Heart Journal, 2020, 229, 1-17.	1.2	85
878	Left Ventricular End-Systolic Volume Is a Reliable Predictor of New-Onset Heart Failure with Preserved Left Ventricular Ejection Fraction. Cardiology Research and Practice, 2020, 2020, 1-7.	0.5	6
879	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. Digital Biomarkers, 2020, 4, 45-59.	2.2	8
880	Prognostic importance of Kidney, Heart and Interstitial lung diseases (KHI triad) in PH: A machine learning study. Archives of Cardiovascular Diseases, 2020, 113, 630-641.	0.7	3
881	Cause of Death in Patients With Acute Heart Failure. JACC: Heart Failure, 2020, 8, 999-1008.	1.9	12
882	Aldosterone. JACC: Heart Failure, 2020, 8, 1021-1023.	1.9	1
883	Effectiveness and safety of Baduanjin exercise (BDJE) on heart failure with preserved left ventricular ejection fraction (HFpEF). Medicine (United States), 2020, 99, e22994.	0.4	3
884	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	1.9	15
885	Sex Differences in HFpEF. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	2

#	ARTICLE	IF	CITATIONS
886	The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives. <i>Journal of Human Hypertension</i> , 2020, 35, 1029-1037.	1.0	10
887	Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e018827.	1.6	23
888	Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?. <i>Current Diabetes Reports</i> , 2020, 20, 75.	1.7	11
889	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	2.9	93
890	Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016009.	1.6	8
891	Geographic variation in the statin trials: Underrepresentation of Asian populations. <i>International Journal of Cardiology</i> , 2020, 316, 249-251.	0.8	3
892	Trends in cause-specific readmissions in heart failure with preserved vs. reduced and mid-range ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2894-2903.	1.4	13
893	Sympathetic activation and outcomes in chronic heart failure: Does the neurohormonal hypothesis apply to mid-range and preserved ejection fraction patients?. <i>European Journal of Internal Medicine</i> , 2020, 81, 60-66.	1.0	14
894	Training general practitioners to improve evidence-based drug treatment of patients with heart failure: a cluster randomised controlled trial. <i>Netherlands Heart Journal</i> , 2020, 28, 604-612.	0.3	2
895	Exercise Training Effects on the Relationship of Physical Function and Health-Related Quality of Life Among Older Heart Failure Patients With Preserved Ejection Fraction. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2020, 40, 427-433.	1.2	19
896	Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 579400.	1.1	2
897	Management of chronic heart failure. <i>Clinics in Integrated Care</i> , 2020, 2, 100016.	0.3	0
898	Associations Between Depressive Symptoms and HFpEF-Related Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 1009-1020.	1.9	19
899	Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. <i>The Cochrane Library</i> , 2020, 2020, CD007004.	1.5	41
900	Sex-specific differences in access and response to medical and device therapies in heart failure: State of the art. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 640-648.	1.6	5
901	Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction. <i>Current Hypertension Reports</i> , 2020, 22, 82.	1.5	13
902	Heart Failure With Preserved Ejection Fraction: Defining Phenotypes. <i>Journal of Cardiac Failure</i> , 2020, 26, 929-931.	0.7	0
903	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. <i>EMBO Molecular Medicine</i> , 2020, 12, e10865.	3.3	104

#	ARTICLE	IF	CITATIONS
904	Targeting Ca ²⁺ + Handling Proteins for the Treatment of Heart Failure and Arrhythmias. <i>Frontiers in Physiology</i> , 2020, 11, 1068.	1.3	16
905	Awareness of Physicians in Yemen Toward High Blood Pressure Management According to the Eighth Joint National Committee (JNC 8) Guideline. <i>International Journal of General Medicine</i> , 2020, Volume 13, 529-537.	0.8	2
906	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2020, 142, 1725-1735.	1.6	77
907	Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. <i>Current Cardiology Reports</i> , 2020, 22, 140.	1.3	43
908	Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 769-785.	0.9	16
909	Spirolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016239.	1.6	20
910	Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEF. <i>Journal of the American Heart Association</i> , 2020, 9, e018396.	1.6	2
911	Right ventricle in heart failure with preserved ejection fraction. <i>Heart</i> , 2020, 106, 1798-1804.	1.2	23
912	Atrial Functional Mitral and Tricuspid Regurgitation. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	5
913	Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor. <i>Current Cardiovascular Risk Reports</i> , 2020, 14, 1.	0.8	6
914	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
915	Spirolactone: diuretic or disease-modifying drug in heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2020, 22, 1611-1614.	2.9	2
916	Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e015103.	1.6	37
917	Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction. <i>Biomarkers</i> , 2020, 25, 556-565.	0.9	15
919	Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 68-77.	3.0	12
920	Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 878-883.	1.0	4
921	Comparison between Spirolactone and Eplerenone on LV Systolic Function in Patients with Chronic Heart Failure. <i>University Heart Journal</i> , 2020, 16, 65-70.	0.0	1
922	Comparison of Patient Self-reported Health Status With Clinician-Assigned New York Heart Association Classification. <i>JAMA Network Open</i> , 2020, 3, e2014319.	2.8	17

#	ARTICLE	IF	CITATIONS
923	Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2408-2419.	1.4	10
924	Low serum potassium levels and diabetes - An unfavorable combination in patients with heart failure and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2020, 317, 121-127.	0.8	4
925	Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas. <i>ESC Heart Failure</i> , 2020, 7, 1676-1687.	1.4	9
926	Reappraisal on pharmacological and mechanical treatments of heart failure. <i>Cardiovascular Diabetology</i> , 2020, 19, 55.	2.7	27
927	Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. <i>International Journal of Obesity</i> , 2020, 44, 1561-1567.	1.6	26
928	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 570-584.	1.6	53
929	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , 2020, 22, 1615-1624.	2.9	24
930	Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 1600-1610.	2.9	15
931	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	1.9	17
932	Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-7.	0.5	6
933	Role of Leptin in Cardiovascular Diseases. <i>Frontiers in Endocrinology</i> , 2020, 11, 354.	1.5	94
934	Advances in the Management of Acute Decompensated Heart Failure. <i>Medical Clinics of North America</i> , 2020, 104, 601-614.	1.1	7
935	Left ventricular contractile performance and heart failure in patients with left ventricular ejection fraction more than 40%. <i>Heart and Vessels</i> , 2020, 35, 1689-1698.	0.5	3
936	Implications of Kidney Disease in the Cardiac Patient. <i>Interventional Cardiology Clinics</i> , 2020, 9, 265-278.	0.2	2
937	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , 2020, 316, 172-179.	0.8	15
938	Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.7	
939	Effect of renin-angiotensin system inhibition on cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2020, 26, 1477-1484.	1.7	4
940	Management of neurogenic orthostatic hypotension in the heart failure patient. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2020, 227, 102691.	1.4	5

#	ARTICLE	IF	CITATIONS
941	Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?. <i>JACC: Heart Failure</i> , 2020, 8, 369-371.	1.9	2
942	Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2020, 9, e015026.	1.6	30
943	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. <i>JACC: Heart Failure</i> , 2020, 8, 347-358.	1.9	53
944	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	1.9	14
945	Angiotensin Receptor-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1180-1183.	13.9	21
946	Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1281-1295.	1.2	116
947	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1644-1656.	1.2	46
948	Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes. <i>ESC Heart Failure</i> , 2020, 7, 811-824.	1.4	11
949	Understanding the results of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1531-1535.	2.9	7
950	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1358-1365.	1.5	11
951	Coronary Artery Disease: Therapeutics and Drug Discovery. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	4
952	Evaluation and management of heart failure with preserved ejection fraction. <i>Nature Reviews Cardiology</i> , 2020, 17, 559-573.	6.1	339
953	Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure. <i>Circulation</i> , 2020, 141, 1463-1476.	1.6	42
954	Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. <i>ESC Heart Failure</i> , 2020, 7, 381-399.	1.4	31
955	Spironolactone in pulmonary arterial hypertension: results of a crossover study. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	0.8	22
956	Sex-specific difference in the association between arterial stiffness and subclinical left ventricular dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 817-823.	0.5	7
957	Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2752-2761.	1.4	9
958	Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials. <i>Circulation: Heart Failure</i> , 2020, 13, e006720.	1.6	22

#	ARTICLE	IF	CITATIONS
959	Variability of Myocardial Strain During Isometric Exercise in Subjects With and Without Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 111.	1.1	13
960	Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. <i>ESC Heart Failure</i> , 2020, 7, 2561-2571.	1.4	5
961	PGI2 Analog Attenuates Salt-Induced Renal Injury through the Inhibition of Inflammation and Rac1-MR Activation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4433.	1.8	7
962	Regional adiposity and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1540-1550.	2.9	69
963	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. <i>European Journal of Heart Failure</i> , 2020, 22, 1076-1096.	2.9	96
964	Heart Failure with Preserved Ejection Fraction—a Concise Review. <i>Current Cardiology Reports</i> , 2020, 22, 82.	1.3	40
965	Response to beta-blockers and natriuretic peptide level in acute heart failure: analysis of data from the Korean acute heart failure registry. <i>Clinical Research in Cardiology</i> , 2020, 110, 1392-1403.	1.5	1
966	CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 763-772.	1.3	8
967	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020, 22, 1065-1075.	2.9	31
968	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	1.4	23
969	Secrets of spironolactone: continuing insights from TOPCAT Americas. <i>European Journal of Heart Failure</i> , 2020, 22, 1625-1627.	2.9	0
970	Mineralocorticoid receptor antagonist use following heart failure hospitalization. <i>ESC Heart Failure</i> , 2020, 7, 482-492.	1.4	10
971	Anemia, Mortality, and Hospitalizations in Heart Failure With a Preserved Ejection Fraction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	22
972	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , 2020, 2020, CD012466.	1.5	7
973	Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 21-31.	0.8	1
974	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 834-844.	2.9	36
975	Cardiac phenotype in propionic acidemia — Results of an observational monocentric study. <i>Molecular Genetics and Metabolism</i> , 2020, 130, 41-48.	0.5	14
976	Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists. <i>Current Hypertension Reports</i> , 2020, 22, 21.	1.5	25

#	ARTICLE	IF	CITATIONS
978	Design and synthesis of two new steroid derivatives with biological activity on heart failure via the M2-muscarinic receptor activation. <i>Steroids</i> , 2020, 158, 108620.	0.8	4
979	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. <i>European Journal of Heart Failure</i> . 2020. 22. 1711-1723.	2.9	43
980	Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 9-17.	1.0	25
981	Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 336-344.	1.4	12
982	Loss of myeloid differentiation protein 1 promotes atrial fibrillation in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 626-638.	1.4	11
983	Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 125, 1187-1193.	0.7	26
984	Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 255-257.	1.2	4
985	An overview of hypertension and cardiac involvement in Asia: Focus on heart failure. <i>Journal of Clinical Hypertension</i> , 2020, 22, 423-430.	1.0	27
986	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006638.	1.6	12
987	Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. <i>PLoS ONE</i> , 2020, 15, e0232280.	1.1	28
988	Mythical metrics and methods: Needed paradigm shift in disease recognition and therapy. <i>Medical Hypotheses</i> , 2020, 141, 109734.	0.8	0
989	Managing heart failure with preserved ejection fraction. <i>Annals of Translational Medicine</i> , 2020, 8, 395-395.	0.7	7
990	Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1392-1401.	1.5	21
991	Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 933-937.	1.4	3
992	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , 2020, 109, 1079-1098.	1.5	74
994	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	0.7	7
995	Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>American Journal of Medicine</i> , 2020, 133, 1187-1194.	0.6	9
996	The Challenges of NT-proBNP Testing in AHFpEF. <i>JACC: Heart Failure</i> , 2020, 8, 382-385.	1.9	12

#	ARTICLE	IF	CITATIONS
997	Heart Failure With Preserved Ejection Fraction: Where Do We Stand?. Mayo Clinic Proceedings, 2020, 95, 629-631.	1.4	2
998	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. Journal of Clinical Medicine, 2020, 9, 1110.	1.0	19
999	Heart failure management in dialysis patients: Many treatment options with no clear evidence. Seminars in Dialysis, 2020, 33, 198-208.	0.7	20
1000	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 2020, 22, 898-901.	2.9	59
1001	Mega-trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	2.9	11
1002	Age and biomarkers in heart failure: challenging the current model to select patients for clinical trials. European Journal of Heart Failure, 2020, 22, 2089-2092.	2.9	1
1003	Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold. European Journal of Heart Failure, 2020, 22, 1006-1008.	2.9	4
1004	From PARADIGM to PARAGON further evidence supporting continuous heart failure spectrum. European Journal of Heart Failure, 2020, 22, 1536-1539.	2.9	5
1005	Specialty-Based Variability in Diagnosing and Managing Heart Failure With Preserved Ejection Fraction. Mayo Clinic Proceedings, 2020, 95, 669-675.	1.4	6
1006	Hemodynamic Determinants of Age Versus Left Ventricular Diastolic Function Relations Across the Full Adult Age Range. Hypertension, 2020, 75, 1574-1583.	1.3	15
1007	Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices. Current Topics in Medicinal Chemistry, 2020, 20, 266-271.	1.0	0
1008	Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy. Keio Journal of Medicine, 2020, 69, 77-87.	0.5	4
1009	H2FPEF score predicts 1-year rehospitalisation of patients with heart failure with preserved ejection fraction. Postgraduate Medical Journal, 2021, 97, 164-167.	0.9	11
1010	Sodium-glucose cotransporter-2 inhibitors represent a paradigm shift in the prevention of heart failure in type-2 diabetes patients. Journal of Diabetes Investigation, 2021, 12, 6-20.	1.1	17
1011	Human Immunodeficiency Virus-Associated Myocardial Diastolic Dysfunction and Soluble ST2 Concentration in Tanzanian Adults: A Cross-Sectional Study. Journal of Infectious Diseases, 2021, 223, 83-93.	1.9	5
1012	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1839-1859.	0.6	30
1013	Cumulative events in the TOPCAT trial. European Journal of Heart Failure, 2021, 23, 491-492.	2.9	0
1014	Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. European Journal of Internal Medicine, 2021, 85, 41-49.	1.0	11

#	ARTICLE	IF	CITATIONS
1015	Heart failure epidemiology and treatment in primary care: a retrospective cross-sectional study. ESC Heart Failure, 2021, 8, 489-497.	1.4	11
1016	Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology. Cardiovascular Research, 2021, 117, 999-1014.	1.8	47
1017	Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovascular Research, 2021, 117, 423-434.	1.8	102
1018	Mineralocorticoid receptor antagonists in patients with chronic kidney disease. , 2021, 219, 107701.		13
1019	Sex-specific cardiac and vascular responses to hypertension in Chinese populations without overt cardiovascular diseases. Postgraduate Medicine, 2021, 133, 181-187.	0.9	5
1020	Renal Denervation to Treat Heart Failure. Annual Review of Physiology, 2021, 83, 39-58.	5.6	28
1021	ABCs of Heart Failure (HFpEF) Management: Guide for Nurse Practitioners. Journal for Nurse Practitioners, 2021, 17, 168-173.	0.4	0
1022	Event-specific win ratios and testing with terminal and non-terminal events. Clinical Trials, 2021, 18, 180-187.	0.7	2
1023	SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Failure Reviews, 2021, 26, 623-642.	1.7	41
1024	Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data. Pharmacological Research, 2021, 163, 105332.	3.1	23
1025	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. Postgraduate Medicine, 2021, 133, 125-139.	0.9	8
1026	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 2021, 110, 1234-1248.	1.5	8
1027	Impact of catheter ablation for atrial fibrillation on cardiac disorders in patients with coexisting heart failure. ESC Heart Failure, 2021, 8, 670-679.	1.4	9
1028	This cat has only eight lives. European Journal of Clinical Investigation, 2021, 51, e13462.	1.7	0
1029	Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. British Journal of General Practice, 2021, 71, e62-e70.	0.7	13
1030	Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). American Journal of Cardiology, 2021, 142, 91-96.	0.7	3
1031	ARNI and MRA Combination in PARAGON-HF. JACC: Heart Failure, 2021, 9, 25-27.	1.9	1
1032	Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. CJC Open, 2021, 3, 361-366.	0.7	5

#	ARTICLE	IF	CITATIONS
1033	Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 247-253.	1.1	5
1034	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161.	1.0	249
1035	Assessing left ventricular systolic function: from ejection fraction to strain analysis. <i>European Heart Journal</i> , 2021, 42, 789-797.	1.0	62
1036	Modes of death in heart failure according to age, sex and left ventricular ejection fraction. <i>Internal and Emergency Medicine</i> , 2021, 16, 643-652.	1.0	4
1037	Combinations of cardiac and non-cardiac predictors for prognoses in patients with acute heart failure. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 83-96.	1.8	7
1038	Association between evidence-based medication at discharge and outcomes in patients with heart failure: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2021, 26, 81-89.	1.7	6
1039	Increased left ventricular end-diastolic pressure after left ventriculography is associated with subsequent congestive heart failure-related hospitalization. <i>International Journal of the Cardiovascular Academy</i> , 2021, 7, 14.	0.1	0
1040	<i>Cardiovascular Medications</i> . , 2021, , 597-642.		1
1041	Echo-Based Approach to the Management of Heart Failure With Preserved Ejection Fraction. , 2021, , 473-488.		0
1042	Cellular and molecular pathobiology of heart failure with preserved ejection fraction. <i>Nature Reviews Cardiology</i> , 2021, 18, 400-423.	6.1	198
1043	Stage D Heart Failure With Preserved Ejection Fraction, Heart Transplantation, and Mechanical Circulatory Support. , 2021, , 276-289.		0
1044	A Survey of Challenges and Opportunities in Sensing and Analytics for Risk Factors of Cardiovascular Disorders. <i>ACM Transactions on Computing for Healthcare</i> , 2021, 2, 1-42.	3.3	3
1045	<i>Molecular, Gene, and Cellular Mechanism</i> . , 2021, , 1-10.		0
1046	Cardiac Mineralocorticoid Receptor and the Na ⁺ /H ⁺ Exchanger: Spilling the Beans. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 614279.	1.1	5
1047	Transcatheter Interatrial Shunts for the Treatment of Heart Failure with Preserved Ejection Fraction. <i>International Journal of Cardiovascular Sciences</i> , 2021, 34, 81-88.	0.0	0
1049	Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 955-960.	0.8	5
1050	Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1299-1306.	1.0	3
1051	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1309-1318.	1.3	4

#	ARTICLE	IF	CITATIONS
1052	Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 1304-1313.	1.4	19
1053	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. <i>ESC Heart Failure</i> , 2021, 8, 1130-1138.	1.4	21
1054	The EMPEROR-Preserved study: end of the search for the “Phoenix” or beginning of a new season for trials in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 4621-4623.	1.0	6
1056	General Principles, Clinical Definition, Epidemiology, and Pathophysiology. , 2021, , 86-92.		0
1057	COVID-19”The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 71.	1.7	33
1058	Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	12
1059	Usefulness of CHADS2, R2CHADS2, and CHA2DS2a-VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients. <i>ESC Heart Failure</i> , 2021, 8, 1369-1377.	1.4	9
1060	Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation. <i>Journal of Korean Medical Science</i> , 2021, 36, e252.	1.1	1
1061	Process evaluation of a randomised pilot trial of home-based rehabilitation compared to usual care in patients with heart failure with preserved ejection fraction and their caregiver’s. <i>Pilot and Feasibility Studies</i> , 2021, 7, 11.	0.5	9
1062	Korunmu” ejeksiyon fraksiyonlu kalp yetmezli”i. <i>Ege Tıp Dergisi</i> , 0, , 94-97.	0.1	0
1063	Ventricular”Arterial Interaction in Patients With Heart Failure and a Preserved Ejection Fraction. , 2021, , 71-85.		0
1064	Chronic heart failure and adherence to medication: methods for assessing adherence to therapy and unresolved issues. <i>Klinicist</i> , 2021, 14, 18-28.	0.1	2
1065	Pharmacotherapeutic principles of fluid management in heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 595-610.	0.9	2
1066	The effect of spironolactone on diastolic function in haemodialysis patients. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1927-1936.	0.7	4
1067	Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Cureus</i> , 2021, 13, e13604.	0.2	0
1069	Mineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload”Induced Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007279.	1.6	15
1070	Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. <i>ESC Heart Failure</i> , 2021, 8, 842-848.	1.4	24
1071	Sodium”glucose co”transporter 2 inhibitors”the first successful treatment for heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2021, 23, 1256-1259.	2.9	2

#	ARTICLE	IF	CITATIONS
1072	Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 89-99.	1.9	18
1073	Design and Synthesis of an Aniline Derivative with Biological Activity on Heart Failure. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 24, 220-232.	0.6	0
1074	New Hemodynamic Insights in Pulmonary Vascular Disease and Heart Failure with Preserved Ejection Fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	0
1075	Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3398-3412.	1.8	3
1076	A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-100.	0.4	8
1077	C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial. <i>BMC Medicine</i> , 2021, 19, 44.	2.3	11
1078	Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems. <i>ESC Heart Failure</i> , 2021, 8, 2089-2102.	1.4	21
1079	Prognostic significance of the HFA-PEFF score in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2154-2164.	1.4	27
1080	Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1211-1221.	1.2	19
1081	NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 498-507.	2.3	18
1082	Diretrizes Brasileiras de Hipertensão Arterial – 2020. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 516-658.	0.3	340
1083	Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps. <i>Journal of the American Heart Association</i> , 2021, 10, e017684.	1.6	10
1084	The Battle for Enrollment. <i>JACC: Heart Failure</i> , 2021, 9, 212-214.	1.9	0
1085	Learning health systems using data to drive healthcare improvement and impact: a systematic review. <i>BMC Health Services Research</i> , 2021, 21, 200.	0.9	59
1086	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13
1087	Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 146-157.	1.8	56
1088	The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications. , 0, , .		0
1089	The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. <i>JACC: Heart Failure</i> , 2021, 9, 169-178.	1.9	39

#	ARTICLE	IF	CITATIONS
1090	Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-10.	1.0	8
1091	Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs. <i>Journal of Veterinary Internal Medicine</i> , 2021, 35, 1245-1254.	0.6	4
1092	Differences in risk profiles and long-term outcomes in acute heart failure patients with preserved and reduced left ventricular ejection fraction in the Czech Republic: The AHEAD registry sub-analysis. <i>Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia</i> , 2021, 165, 34-42.	0.2	0
1093	Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 954-963.	2.9	24
1094	Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. <i>Annals of Translational Medicine</i> , 2021, 9, 523-523.	0.7	1
1095	Sex Differences in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e018574.	1.6	85
1096	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	2.9	630
1098	Position of Patients with Mid-Range Ejection Fraction in the General Chronic Heart Failure Population. <i>Russian Archives of Internal Medicine</i> , 2021, 11, 111-121.	0.0	2
1099	Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?. <i>Current Opinion in Cardiology</i> , 2021, 36, 413-419.	0.8	12
1100	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1346-1356.	2.9	11
1101	Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3570.	1.8	19
1102	Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	3
1103	The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1319-1341.	0.9	0
1104	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	0.8	170
1105	The CORolla device for energy transfer from systole to diastole: a novel treatment for heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	5
1106	Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 678530.	1.1	6
1107	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. <i>Canadian Journal of Cardiology</i> , 2021, 37, 560-571.	0.8	40
1108	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24

#	ARTICLE	IF	CITATIONS
1109	Association Between Physical Status and the Effects of Combination Therapy With Renin-Angiotensin System Inhibitors and β -Blockers in Patients With Acute Heart Failure. <i>Circulation Reports</i> , 2021, 3, 217-226.	0.4	2
1110	Estimated Glomerular Filtration Rate Is Associated With an Increased Risk of Death in Heart Failure Patients With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 643358.	1.1	3
1111	Future of Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Nephropathy. <i>Cardiologia Croatica</i> , 2021, 16, 157-163.	0.0	0
1112	Living Alone and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Psychosomatic Medicine</i> , 2021, 83, 470-476.	1.3	6
1113	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	0.7	362
1114	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. <i>European Heart Journal</i> , 2021, 42, 1825-1857.	1.0	342
1115	The E/e [™] Ratio's Role in Risk Stratification of Acute Heart Failure with Preserved Ejection Fraction. <i>Medicina (Lithuania)</i> , 2021, 57, 375.	0.8	6
1116	Risk Stratification Towards Precision Medicine in Heart Failure's Current Progress and Future Perspectives. <i>Circulation Journal</i> , 2021, 85, 576-583.	0.7	6
1117	Spirolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	4
1118	Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives. <i>Russian Journal of Cardiology</i> , 2021, 26, 4436.	0.4	3
1119	Insuffisance cardiaque et diabète: données épidémiologiques, phénotype et impact sur le pronostic. <i>Medicine Des Maladies Metaboliques</i> , 2021, 15, 246-251.	0.1	1
1120	Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 667990.	1.6	7
1121	Sex and Heart Failure Treatment Prescription and Adherence. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 630141.	1.1	5
1122	Association Between β -Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1165-1174.	0.7	17
1123	Outcomes among acute heart failure emergency department patients by preserved vs. reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2889-2898.	1.4	7
1124	Spirolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 632978.	1.6	4
1125	Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 678121.	1.1	6
1126	Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1569-1581.	0.8	2

#	ARTICLE	IF	CITATIONS
1127	Pharmacological Management of Heart Failure: A Century of Expert Opinions in Cecil Textbook of Medicine. <i>American Journal of Therapeutics</i> , 2021, 28, e292-e298.	0.5	4
1128	Sex differences in the longitudinal relationship of low-grade inflammation and echocardiographic measures in the Hoorn and FLEMENGHO Study. <i>PLoS ONE</i> , 2021, 16, e0251148.	1.1	2
1129	Deep-Learning Models for the Echocardiographic Assessment of Diastolic Dysfunction. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1887-1900.	2.3	57
1130	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.4	30
1131	Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021, 77, 1549-1558.	1.3	16
1132	S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction. <i>Circulation</i> , 2021, 143, 1912-1925.	1.6	28
1133	Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies. <i>ESC Heart Failure</i> , 2021, 8, 3327-3338.	1.4	3
1134	Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 146, 36-47.	0.7	15
1135	Left atrial assist device for heart failure with preserved ejection fraction: initial results with torque control mode in diastolic heart failure model. <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	8
1136	Sex-related differences in the pharmacological treatment of heart failure. , 2022, 229, 107891.		14
1137	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. <i>The Cochrane Library</i> , 2021, 2021, CD012721.	1.5	19
1138	Cardiac Amyloidosis for the Primary Care Provider: A Practical Review to Promote Earlier Recognition of Disease. <i>American Journal of Medicine</i> , 2021, 134, 587-595.	0.6	5
1139	Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 618816.	1.1	13
1140	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1522-1545.	0.3	47
1141	Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). <i>American Journal of Cardiology</i> , 2021, 148, 146-150.	0.7	15
1142	Falla cardiaca con fracci3n de eyecci3n preservada: generalidades y aproximaci3n en el perioperatorio. <i>Revista Med</i> , 2021, 28, 49-60.	0.1	0
1143	Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. <i>Pharmaceuticals</i> , 2021, 14, 561.	1.7	16
1144	Reply. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1262-1263.	1.1	0

#	ARTICLE	IF	CITATIONS
1145	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1217-1225.	2.9	195
1147	External validation of a claims-based model to predict left ventricular ejection fraction class in patients with heart failure. <i>PLoS ONE</i> , 2021, 16, e0252903.	1.1	13
1148	Correspondence. <i>Deutsches A&#x0308;rzteblatt International</i> , 2021, 118, 434.	0.6	0
1149	Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 689591.	1.1	5
1150	Characterization of hemodynamic and metabolic abnormalities in the heart failure spectrum: the role of combined cardiopulmonary and exercise echocardiography stress test. <i>Minerva Cardiology and Angiology</i> , 2022, 70, .	0.4	26
1151	Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 685-698.	0.8	3
1152	Valve Academic Research Consortium 3: Updated Endpoint Definitions for AorticÂValve Clinical Research. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2717-2746.	1.2	416
1153	Diving Into the Diagnostic Score Algorithms of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665424.	1.1	4
1154	Treatment for hyperkalaemia in heart failure: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
1155	Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 681726.	1.1	7
1156	High Neutrophil to Lymphocyte Ratio and Its Gene Signatures Correlate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 614757.	1.1	19
1157	Recent advances in pharmacological treatment of heart failure. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13624.	1.7	19
1158	Decoding empagliflozinâ€™s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 12025.	1.6	23
1159	Insuficiencia cardÃaca con fracciÃ³n de eyecciÃ³n ventricular preservada. <i>Medicine</i> , 2021, 13, 2037-2044.	0.0	0
1160	Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia. <i>Internal Medicine</i> , 2021, 60, 2093-2095.	0.3	2
1161	Heart failure with preserved ejection fraction based on aging and comorbidities. <i>Journal of Translational Medicine</i> , 2021, 19, 291.	1.8	14
1162	Leukocyte count and the risk of adverse outcomes in patients with HFpEF. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 333.	0.7	5
1163	Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options. <i>Medical Herald of the South of Russia</i> , 2021, 12, 6-15.	0.2	1

#	ARTICLE	IF	CITATIONS
1164	Hypertension and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 337-343.	1.0	6
1165	Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 483-498.	1.0	14
1166	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. <i>European Journal of Heart Failure</i> , 2021, 23, 1250-1255.	2.9	17
1167	Emerging trends in cardiovascular research: HFpEF in the spotlight. A bibliometric analysis of the years 2009-2016. <i>Minerva Medica</i> , 2021, 112, 506-513.	0.3	3
1168	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7650.	1.8	17
1169	Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction. <i>PLoS ONE</i> , 2021, 16, e0254641.	1.1	8
1170	Difference in Prognosis between Continuation and Discontinuation of A 5-Month Cardiac Rehabilitation Program in Outpatients with Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2021, 10, 3306.	1.0	1
1171	Management of Pulmonary Hypertension in Left Heart Disease. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 115.	0.5	7
1172	Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 377-386.	1.0	5
1173	Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction. <i>Science China Life Sciences</i> , 2021, , 1.	2.3	5
1174	Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review. <i>Current Vascular Pharmacology</i> , 2022, 20, 46-51.	0.8	5
1175	Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 315-326.	1.0	18
1176	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 463-482.	1.0	4
1177	Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1541-1551.	2.9	12
1178	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. <i>Journal of Cardiac Failure</i> , 2021, 27, 816-818.	0.7	0
1179	Renal Dysfunction and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 357-367.	1.0	9
1180	Current and emerging drug targets in heart failure treatment. <i>Heart Failure Reviews</i> , 2022, 27, 1119-1136.	1.7	22
1181	Left ventricular diastolic pressure gradient and outcome in advanced chronic kidney disease patients with preserved ejection fraction. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2663-2673.	0.7	4

#	ARTICLE	IF	CITATIONS
1182	Naive Bayes Prediction of the Development of Cardiac Events in Heart Failure With Preserved Ejection Fraction in an Outpatient Clinicâ€”Beyond B-Type Natriuretic Peptide â€”. Circulation Journal, 2021, 86, .	0.7	6
1183	Survival analyses in cardiovascular research, part II: statistical methods in challenging situations. Revista Espanola De Cardiologia (English Ed), 2022, 75, 77-85.	0.4	16
1184	Obesity and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 345-356.	1.0	9
1185	Can mechanical circulatory support be an effective treatment for HFpEF patients?. Heart Failure Reviews, 2021, , 1.	1.7	4
1186	Neutrophils proâ€”inflammatory and antiâ€”inflammatory cytokine release in patients with heart failure and reduced ejection fraction. ESC Heart Failure, 2021, 8, 3855-3864.	1.4	9
1187	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. Blood Pressure, 2021, 30, 269-281.	0.7	8
1188	Prognostic Impact of Echocardiographic Diastolic Dysfunction on Outcomes in Patients With Heart Failure With Preserved Ejection Fractionâ€”Insights From the PURSUIT-HFpEF Registry â€”. Circulation Journal, 2021, 86, 23-33.	0.7	9
1189	Angiotensin 1 release from human neutrophils is independent from neutrophil extracellular traps (NETs). BMC Immunology, 2021, 22, 51.	0.9	2
1190	Predictors of longâ€”term outcome in heart failure with preserved ejection fraction: a followâ€”up from the <sc>KaRen</sc> study. ESC Heart Failure, 2021, 8, 4243-4254.	1.4	13
1191	Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 707162.	1.1	9
1192	Sacubitrilâ€”valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 2021, 42, 3741-3752.	1.0	74
1194	Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials. Circulation, 2021, 144, 1193-1195.	1.6	34
1195	Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Eventsâ€”Application to Clinical Trials in Chronic Heart Failure. Statistics in Biopharmaceutical Research, 2023, 15, 268-279.	0.6	9
1196	Increasing Participation of Women in Cardiovascular Trials. Journal of the American College of Cardiology, 2021, 78, 737-751.	1.2	60
1197	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605.	1.2	3
1198	A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 3495-3503.	1.4	3
1199	Pulmonary Hypertension in the Context ofâ€”Heart Failure With Preserved Ejection Fraction. Chest, 2021, 160, 2232-2246.	0.4	14
1200	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. European Heart Journal, 2021, 42, 4420-4430.	1.0	65

#	ARTICLE	IF	CITATIONS
1201	Poorer Exercise Accommodation of Regional Systolic Myocardial Motion after Spironolactone Treatment in Heart Failure Patients with Preserved Ejection Fraction and Ventricular Dyssynchrony. <i>Journal of Clinical Medicine</i> , 2021, 10, 3827.	1.0	1
1202	Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation. <i>European Journal of Internal Medicine</i> , 2021, 94, 73-84.	1.0	5
1203	Health-Related Quality of Life in the <u>Spi</u>ronolactone to <u>R</u>educer <u>k</u>CD <u>T</u>herapy (SPIRIT) Trial. <i>Clinical Nursing Research</i> , 2022, 31, 588-597.	0.7	0
1204	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
1205	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019545.	1.6	29
1206	Iron therapy in iron-deficiency patients with heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2021, 100, e26919.	0.4	1
1207	Blood pressure visit-to-visit variability and outcomes in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3984-3996.	1.4	4
1208	Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. <i>Annual Review of Medicine</i> , 2022, 73, 321-337.	5.0	52
1210	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
1211	Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. <i>Circulation Reports</i> , 2021, 3, 440-448.	0.4	18
1212	Sensitization of nontoxic MOF for their potential drug delivery application against microbial infection. <i>Inorganica Chimica Acta</i> , 2021, 523, 120381.	1.2	50
1213	Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 772-795.	1.9	24
1214	High-Intensity Interval Training for Heart Failure Patients With Preserved Ejection Fraction (HIT-HF)-Rational and Design of a Prospective, Randomized, Controlled Trial. <i>Frontiers in Physiology</i> , 2021, 12, 734111.	1.3	6
1216	Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 698117.	1.1	7
1217	Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008284.	1.6	6
1218	Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials. <i>JACC: Heart Failure</i> , 2021, 9, 803-806.	1.9	3
1219	Bayesian Analyses of Cardiovascular Trials – Bringing Added Value to the Table. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1415-1427.	0.8	3
1220	Opportunities and challenges for artificial intelligence in clinical cardiovascular genetics. <i>Trends in Genetics</i> , 2021, 37, 780-783.	2.9	1

#	ARTICLE	IF	CITATIONS
1221	NR3C2 Genotype is Associated with Response to Spironolactone in Diastolic Heart Failure Patients from the Aldoâ€œDHF Trial. <i>Pharmacotherapy</i> , 2021, , .	1.2	7
1222	Plasma and urine biomarkers in chronic kidney disease: closer to clinical application. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 531-537.	1.0	12
1223	Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. <i>Drugs - Real World Outcomes</i> , 2022, 9, 53-62.	0.7	5
1224	Importance of Internal Variability in Clinical Trials of Cardiovascular Disease. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1404-1414.	0.8	0
1225	Percutaneous edgeâ€œtoâ€œedge mitral valve repair for mitral regurgitation improves heart failure symptoms in heart failure with preserved ejection fraction patients. <i>ESC Heart Failure</i> , 2021, , .	1.4	4
1226	Heart Failure with Preserved Ejection Fraction after Leftâ€œsided Valve Surgery: Prevalent and Relevant. <i>European Journal of Heart Failure</i> , 2021, , .	2.9	5
1227	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1404-1444.	0.7	60
1228	Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2021, 20, 180.	2.7	13
1229	Autonomic regulation device therapy in patients with heart failure with preserved ejection fraction. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0150.	0.0	0
1230	Heart failure with mid-range or mildly reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2022, 19, 100-116.	6.1	156
1231	Integrating High-Sensitivity Troponin T andâ€œSacubitril/Valsartan Treatment inâ€œHFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	1.9	21
1232	State-of-the-Art Review of Current Therapies for HFpEF: An Overview of Interatrial Septal Device Therapy in Heart Failure. <i>Current Cardiology Reviews</i> , 2021, 17, e230421189012.	0.6	1
1233	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. <i>Circulation Journal</i> , 2021, 85, 2252-2291.	0.7	80
1234	Clinical Trials of Heart Failure: Is There a Question of Sex?. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1303-1309.	0.8	3
1235	Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis. <i>JACC: Heart Failure</i> , 2021, 9, 795-802.	1.9	17
1236	An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1017-1023.	1.9	10
1237	Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166208.	1.8	17
1238	Advanced Heart Failure in a Special Population. <i>Heart Failure Clinics</i> , 2021, 17, 685-695.	1.0	1

#	ARTICLE	IF	CITATIONS
1239	Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders â New perspectives for combination therapy. <i>Pharmacological Research</i> , 2021, 172, 105859.	3.1	37
1240	Biomaterials based cardiac patches for the treatment of myocardial infarction. <i>Journal of Materials Science and Technology</i> , 2021, 94, 77-89.	5.6	24
1241	Evaluation of patients with heart failure. , 2022, , 51-76.		0
1242	Heart Failure and Pulmonary Hypertension. , 2022, , 217-255.		0
1243	Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2020, 11, 571106.	1.6	2
1244	General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials. , 2021, , 463-472.		0
1245	Chronische Herzinsuffizienz. , 2021, , 92-109.		0
1246	Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. <i>Journal of Hypertension</i> , 2021, 39, 1378-1385.	0.3	4
1247	Hypertension and Its Relation to Heart Failure With a Preserved Ejection Fraction. , 2021, , 258-267.		0
1248	Clinical Phenotypes and Age-Related Differences in Presentation, Treatment, and Outcome of Heart Failure with Preserved Ejection Fraction: A Vietnamese Multicenter Research. <i>Cardiology Research and Practice</i> , 2021, 2021, 1-9.	0.5	5
1249	Interleukinâ1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (DâHART2</scp>). <i>Clinical Cardiology</i> , 2017, 40, 626-632.	0.7	56
1250	Characterization of the <scp>inflammatoryâmetabolic</scp> phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. <i>European Journal of Heart Failure</i> , 2020, 22, 1551-1567.	2.9	93
1251	Multicenter Trials. , 2015, , 501-518.		5
1253	Hypertension Drug Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1177, 149-268.	0.8	6
1254	Management and Care of Older Cardiac Patients. , 2018, , 245-265.		6
1255	Pulmonary Hypertension with Left Heart Disease: Prevalence, Temporal Shifts in Etiologies and Outcome. <i>American Journal of Medicine</i> , 2017, 130, 1272-1279.	0.6	32
1256	Medication Burden in Older Patients With Heart Failure: A Cohort Study of Medicare Beneficiaries. <i>Journal of Cardiac Failure</i> , 2020, 26, 742-744.	0.7	2
1258	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117

#	ARTICLE	IF	CITATIONS
1259	The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. <i>European Heart Journal Supplements</i> , 2020, 22, L77-L81.	0.0	15
1260	Diastolic Heart Failure. <i>Cardiology in Review</i> , 2021, 29, 82-88.	0.6	5
1261	The Effects of Preserving Mitral Valve Function on a Left Atrial Assist Device: An In Vitro Mock Circulation Loop Study. <i>ASAIO Journal</i> , 2021, 67, 567-572.	0.9	7
1264	Exercise training reverses cardiac aging phenotypes associated with heart failure with preserved ejection fraction in male mice. <i>Aging Cell</i> , 2020, 19, e13159.	3.0	46
1265	Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. <i>JCI Insight</i> , 2018, 3, .	2.3	27
1266	The application of big data to cardiovascular disease: paths to precision medicine. <i>Journal of Clinical Investigation</i> , 2020, 130, 29-38.	3.9	74
1267	Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. <i>Journal of Geriatric Cardiology</i> , 2015, 12, 294-304.	0.2	68
1268	Spironolactone in cardiovascular disease: an expanding universe?. <i>F1000Research</i> , 2017, 6, 1738.	0.8	12
1269	Improved Cardiovascular Disease Outcomes in Older Adults. <i>F1000Research</i> , 2016, 5, 112.	0.8	21
1270	Biomarkers of acute kidney injury and associations with short- and long-term outcomes. <i>F1000Research</i> , 2016, 5, 986.	0.8	20
1271	Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2016, 11, e0145958.	1.1	25
1272	Second thoughts on the final rule: An analysis of baseline participant characteristics reports on ClinicalTrials.gov. <i>PLoS ONE</i> , 2017, 12, e0185886.	1.1	8
1273	Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 97-104.	0.6	3
1274	The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 130-142.	0.6	5
1275	Heart Failure in Women. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 13, 216.	0.5	76
1276	The Management of Heart Failure with Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , 2015, 1, 11.	1.2	20
1277	What the General Practitioner Needs to Know About Their Chronic Heart Failure Patient. <i>Cardiac Failure Review</i> , 2016, 2, 79-84.	1.2	12
1278	Aortic Stenosis and Heart Failure: Disease Ascertainment and Statistical Considerations for Clinical Trials. <i>Cardiac Failure Review</i> , 2019, 5, 99-105.	1.2	19

#	ARTICLE	IF	CITATIONS
1279	Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure. <i>Cardiac Failure Review</i> , 2020, 6, e11.	1.2	21
1280	Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , 2020, 6, e27.	1.2	7
1281	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 4083.	0.4	229
1282	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 4083.	0.4	32
1283	Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis. <i>Brazilian Journal of Medical and Biological Research</i> , 2020, 53, e9646.	0.7	25
1284	Approach to the Treatment of Heart Failure With Preserved Ejection Fraction and Mid- Range Ejection Fraction. <i>International Cardiovascular Forum Journal</i> , 0, 10, .	1.1	2
1285	Association of serum cystatin C levels with mortality in patients with acute type A aortic dissection. <i>Oncotarget</i> , 2017, 8, 101103-101111.	0.8	6
1286	Management of heart failure with preserved ejection fraction. <i>Australian Prescriber</i> , 2020, 43, 12-17.	0.5	6
1287	Role of spironolactone in the treatment of heart failure with preserved ejection fraction. <i>Annals of Translational Medicine</i> , 2018, 6, 461-461.	0.7	14
1288	Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction—results of a meta-analysis of randomized controlled trials. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 272-287.	0.7	3
1289	The Role of Mineralocorticoid Receptor Antagonists in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmaceutical Design</i> , 2019, 24, 5525-5527.	0.9	2
1290	Adverse Effects of Mineralocorticoid Receptor Antagonist Administration. <i>Current Pharmaceutical Design</i> , 2019, 24, 5537-5541.	0.9	12
1291	Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1818-1849.	1.0	22
1292	Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. <i>Health Technology Assessment</i> , 2017, 21, 1-150.	1.3	21
1293	The Role of Arterial Stiffness and Central Hemodynamics in Heart Failure. <i>International Journal of Heart Failure</i> , 2020, 2, 209.	0.9	15
1294	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1-14.	0.7	13
1295	Heart failure with preserved ejection fraction: insights from recent clinical researches. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 514-534.	0.7	10
1297	Current status of heart failure: global and Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 487-497.	0.7	27

#	ARTICLE	IF	CITATIONS
1298	Heart failure guidelines: What you need to know about the 2017 focused update. Cleveland Clinic Journal of Medicine, 2019, 86, 123-139.	0.6	5
1299	CRP Induces NETosis in Heart Failure Patients with or without Diabetes. ImmunoHorizons, 2019, 3, 378-388.	0.8	28
1300	Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research, 2017, 8, 124-131.	0.5	9
1301	Range of adiposity and cardiorenal syndrome. World Journal of Diabetes, 2020, 11, 322-350.	1.3	13
1302	Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World Journal of Cardiology, 2020, 12, 7-25.	0.5	28
1303	Survival after alcohol septal ablation versus conservative therapy in obstructive hypertrophic cardiomyopathy. Cardiology Journal, 2015, 22, 657-664.	0.5	4
1304	Nepriylsin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions. Cardiology Journal, 2016, 23, 591-598.	0.5	10
1305	On the search for the right definition of heart failure with preserved ejection fraction. Cardiology Journal, 2020, 27, 449-468.	0.5	13
1306	InterAtrial Shunt Device (IASD [®]) implantation – a novel treatment method for heart failure with preserved ejection fraction. Kardiologia Polska, 2017, 75, 736-741.	0.3	2
1307	Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease. Drugs in Context, 2020, 9, 1-9.	1.0	7
1308	Sex Differences in Characteristics and Outcomes in Elderly Heart Failure Patients With Preserved Ejection Fraction: A Post-hoc Analysis From TOPCAT. Frontiers in Cardiovascular Medicine, 2021, 8, 721850.	1.1	3
1309	Clinical and pathogenetic features of chronic heart failure with mid-range ejection fraction. Sibirskij Å¾urnal KliniÅeskoj I Åksperimental'noj Mediciny, 2021, 36, 45-50.	0.1	1
1310	Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. Frontiers in Physiology, 2021, 12, 746494.	1.3	56
1311	Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients. ESC Heart Failure, 2021, 8, 5493-5500.	1.4	3
1312	Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction. Circulation Journal, 2023, 87, 1039-1046.	0.7	6
1313	Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction. Medicine, Case Reports and Study Protocols, 2021, 2, e0162.	0.0	0
1314	Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. Therapeutic Innovation and Regulatory Science, 2022, 56, 4-7.	0.8	4
1315	Pharmacotherapy for hypertension-induced left ventricular hypertrophy. The Cochrane Library, 2021, 2021, CD012039.	1.5	3

#	ARTICLE	IF	CITATIONS
1316	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008293.	1.6	18
1317	Mineralocorticoid receptor in cardiovascular diseases—Clinical trials and mechanistic insights. <i>British Journal of Pharmacology</i> , 2022, 179, 3119-3134.	2.7	22
1318	Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial. <i>Cells</i> , 2021, 10, 2796.	1.8	3
1320	EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction. <i>Global Cardiology Science & Practice</i> , 2021, 2021, e202117.	0.3	8
1321	Hemodynamic Congestion at Hospital Discharge Predicts Rehospitalization during Short Term Follow Up in Acute Heart Failure Patients. <i>Indonesian Journal of Cardiology</i> , 2019, 40, .	0.0	1
1324	Acute Decompensated Cardiac Failure. , 2015, , 445-470.		0
1326	Medicatie bij hartfalen. , 2015, , 53-83.		0
1327	Lights and shadows of NOAC international trials—the fruits and future seeds. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2015, 26, 410-419.	0.1	0
1328	Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: Clinical Relevance, Management, and Future Directions. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 88-94.	0.1	0
1329	The effect of combined antihypertensive therapy on left ventricular diastolic function in resting and postexercise patients with arterial hypertension. <i>Aktualna Pitavnica Farmaceutična i Medicinska Nauka i Praktika</i> , 2015, .	0.0	0
1330	Ambulatory Hemodynamic Monitoring of Pulmonary Hypertension. <i>Arrhythmia</i> , 2015, 16, 154-164.	0.0	0
1331	New therapy approach in heart failure with preserved ejection fraction based on new pathophysiological concept. <i>Srca I Krvni Sudovi</i> , 2016, 35, 53-59.	0.1	0
1334	Leitsymptom Dyspnoe, Leistungsschwäche. , 2017, , 115-226.		0
1335	Outpatient Medication Titration in Acute Heart Failure. <i>Contemporary Cardiology</i> , 2017, , 243-258.	0.0	0
1336	Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). , 2017, , 273-339.		0
1337	Heart Failure in Women: Is There a Typical Female Type?. , 2017, , 107-116.		0
1338	Neurohormonal Activation and the Management of Heart Failure. , 2017, , 239-246.		0
1340	Novelties in the treatment of heart failure. <i>Vnitřni Lekarství</i> , 2017, 63, 255-264.	0.1	2

#	ARTICLE	IF	CITATIONS
1341	Chronic Heart Failure. , 2017, , .		0
1342	Training in interventional cardiology in the United States: Program accreditation and physician certification. , 2017, , 633-638.		0
1343	The Concept of Heart Failure: Chronic Diseases Accompanied by an Attack of Acute Exacerbation. , 2018, , 1-15.		1
1344	Acute and Chronic Heart Failure. , 2018, , 237-252.		0
1345	Chronische Herzinsuffizienz. , 2018, , 80-93.		0
1346	Cardiac Disease in Older Adults. , 2018, , 1-21.		0
1347	Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction. US Cardiology Review, 2018, 12, 8-12.	0.5	0
1348	Impact of comorbidities on myocardial remodeling and dysfunction in heart failure with preserved ejection fraction.. Klinicheskaia Meditsina, 2018, 95, 1070-1076.	0.2	1
1349	The year 2017 in cardiology: heart failure. Cardiologia Croatica, 2018, 13, 154-164.	0.0	0
1350	Diab�te et insuffisance cardiaque : donn�es �pid�miologiques et implications th�rapeutiques.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 909-917.	0.0	1
1351	Spirolactone in the treatment of hypertension: a neglected molecule. Vnitri Lekarstvi, 2018, 64, 815-820.	0.1	0
1352	CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: TREATMENT IN CONDITIONS OF LIMITED EVIDENCE. Kuban Scientific Medical Bulletin, 2018, 25, 106-114.	0.1	0
1353	The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition. Drugs in Context, 2018, 7, 1-11.	1.0	0
1355	Heart Failure with Preserved Ejection Fraction. , 2019, , 397-408.		1
1357	Oxidative Stress and Heart Failure. , 2019, , 257-311.		1
1358	Les diur�tiques. , 2019, , 219-236.		0
1359	Mineralocorticoid Receptor Antagonists. , 2019, , 674-680.		0
1360	Fisiopatologia e Tratamento da Insufici�ncia Card�aca com Fra�s�o de Eje�s�o Preservada: Estado da Arte e Perspectivas para o Futuro. Arquivos Brasileiros De Cardiologia, 2019, 114, 120-129.	0.3	2

#	ARTICLE	IF	CITATIONS
1361	Therapie der chronischen Herzinsuffizienz. Pharma-Kritik (discontinued), 2019, 40, .	0.0	0
1362	A review of interventions to improve clinical outcomes following hospitalisation for heart failure. Kardiologia Polska, 2019, 77, 341-346.	0.3	0
1363	Hypertension and atrial fibrillation: a complex problem requiring one comprehensive solution. Medicina Pro Praxi, 2019, 16, 90-96.	0.0	0
1364	1. Pharmacotherapy for Cardiovascular Disease: current status. Japanese Journal of Clinical Pharmacology and Therapeutics, 2019, 50, 99-106.	0.1	0
1365	A Patient with Chronic Kidney Disease and Heart Failure with Preserved. , 2020, , 89-106.		0
1366	Diuretic Therapy Complicated by Hyponatremia. , 2020, , 175-189.		0
1367	Mineralocorticoid Receptor Antagonist Eplerenone in Cardiovascular Disease. Cardiologia Croatica, 2019, 14, 263-269.	0.0	0
1368	Mineralocorticoid Receptor Antagonists. International Cardiovascular Forum Journal, 0, 17, .	1.1	0
1369	The clinical case of familial restrictive cardiomyopathy. Rossiyskiy Vestnik Perinatologii i Pediatrii, 2019, 64, 215-219.	0.1	0
1370	The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology, 2019, , 98-111.	0.4	6
1372	Acute heart failure. , 2019, , 23-34.		0
1373	Outcomes of a Transitional Care Clinic to Reduce Heart Failure Readmissions at an Urban Academic Medical Center. International Journal of Clinical Research & Trials, 2019, 4, .	1.6	4
1375	Leitsymptom Dyspnoe, Leistungsschwäche. , 2020, , 117-229.		0
1376	Reading and Interpreting the Literature on Randomized Controlled Trials. , 2020, , 1-12.		0
1377	Reducing All-cause 30-day Hospital Readmissions for Patients Presenting with Acute Heart Failure Exacerbations: A Quality Improvement Initiative. Cureus, 2020, 12, e7420.	0.2	11
1378	Levoatrial "to" Coronary Sinus Shunting in Heart Failure Therapy. JACC: Cardiovascular Interventions, 2020, 13, 1248-1250.	1.1	1
1379	Heart Failure with Preserved Ejection Fraction and Sudden Death: How to Identify High Risk Patients?. Journal of Cardiac Arrhythmias, 2020, 33, 16-21.	0.1	0
1381	Five-Year Outcomes of Heart Failure with Preserved Ejection Fraction. Open Cardiovascular Medicine Journal, 2020, 14, 18-26.	0.6	3

#	ARTICLE	IF	CITATIONS
1388	Pharmacological Treatment of Chronic Heart Failure. Journal of the Nihon University Medical Association, 2020, 79, 209-215.	0.0	0
1385	Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 656536.	1.1	13
1386	Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. European Journal of Clinical Investigation, 2021, 51, e13401.	1.7	6
1388	Heart Failure in Diabetes Mellitus: An Updated Review. Current Pharmaceutical Design, 2020, 26, 5933-5952.	0.9	3
1389	Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?. Current Opinion in Cardiology, 2021, 36, 211-218.	0.8	0
1390	Classification of Heart Failure: A Farewell to Ejection Fraction?. Anatolian Journal of Cardiology, 2020, 25, 2-6.	0.5	0
1391	Exercise in Specific Diseases: Heart Failure with Preserved Ejection Fraction. , 2020, , 927-955.		0
1392	Novel pharmacotherapies for heart failure. , 2020, , 359-380.		0
1393	Cardiac Disease in Older Adults. , 2020, , 229-249.		0
1394	Novel treatments for diastolic heart failure. , 2020, , 95-127.		0
1395	Chronic Heart Failure. , 2020, , 137-154.		0
1396	The Expanding Class of Mineralocorticoid Receptor Modulators: New Ligands for Kidney, Cardiac, Vascular, Systemic and Behavioral Selective Actions. Acta Endocrinologica, 2020, 16, 487-496.	0.1	6
1397	PARAGON-HF: Lessons Learned and Perspectives. International Journal of Cardiovascular Sciences, 2020, , .	0.0	0
1398	Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?. Cureus, 2020, 12, e7323.	0.2	0
1399	Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e022859.	1.6	19
1400	Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 712-720.	1.4	6
1401	Large animal models of heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, 27, 595-608.	1.7	9
1402	Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction. Hypertension, 2022, 79, 241-250.	1.3	14

#	ARTICLE	IF	CITATIONS
1403	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-42.	0.9	2
1405	Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives. Cardiac Failure Review, 2020, 6, e24.	1.2	3
1407	Does higher SBP at discharge explain better outcomes in non-heart failure with reduced ejection fraction patients? Insights from Fuwai Hospital. Journal of Hypertension, 2021, 39, 356-366.	0.3	0
1410	TÃ³picos Emergentes em InsuficiÃªncia CardÃ¡aca: InsuficiÃªncia CardÃ¡aca com FraÃ§Ã£o de EjeÃ§Ã£o Preservada e IntermediÃ¡ria. Arquivos Brasileiros De Cardiologia, 2020, 115, 949-952.	0.3	3
1412	Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?. Journal - Oklahoma State Medical Association, 2016, 109, 437-8.	0.4	1
1413	Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Medica, 2017, 60, 71-76.	0.3	7
1415	Heart Failure in Older Adults: A Geriatrician Call for Action. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2018, 35, S23-S29.	0.6	0
1416	Heart failure in the elderly. Journal of Geriatric Cardiology, 2021, 18, 219-232.	0.2	3
1418	Dysfunction of resolution receptor triggers cardiomyopathy of obesity and signs of non-resolving inflammation in heart failure. Molecular and Cellular Endocrinology, 2022, 542, 111521.	1.6	0
1419	Left Heart Disease-Related Pulmonary Hypertension. Cardiology Clinics, 2022, 40, 69-76.	0.9	5
1420	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1919.	3.8	72
1421	Event-specific win ratios for inference with terminal and non-terminal events. Statistics in Medicine, 2022, 41, 1225-1241.	0.8	5
1422	Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article. Cureus, 2021, 13, e19398.	0.2	4
1423	Structural and molecular determinants of mineralocorticoid receptor signalling. British Journal of Pharmacology, 2022, 179, 3103-3118.	2.7	27
1424	Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. Clinical Research in Cardiology, 2022, 111, 451-459.	1.5	6
1425	Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. British Journal of Pharmacology, 2022, 179, 3220-3234.	2.7	65
1426	Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2021, 12, 707777.	1.6	8
1428	Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. European Journal of Heart Failure, 2021, , .	2.9	5

#	ARTICLE	IF	CITATIONS
1429	A Natural Language Processingâ€‘Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Network Open, 2021, 4, e2135152.	2.8	21
1430	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation, 2022, 145, 437-447.	1.6	86
1431	How I treat cardiovascular complications in patients with lymphoid malignancies. Blood, 2021, , .	0.6	2
1432	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGONâ€‘HF trial. ESC Heart Failure, 2022, 9, 164-177.	1.4	5
1433	Quality of Life and Exercise Ability in Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1913.	3.8	6
1434	The new antidiabetics in heart disease: can a glycemic holter predict the drug success?. Journal of Cardiology & Current Research, 2021, 14, 170-171.	0.1	0
1436	Ventricular Arrhythmias Among Patients With Advanced Heart Failure: A Populationâ€‘Based Study. Journal of the American Heart Association, 2022, 11, e023377.	1.6	9
1437	Cardiovascular Applications of Artificial Intelligence in Research, Diagnosis, and Disease Management. Advances in Computational Intelligence and Robotics Book Series, 2022, , 80-127.	0.4	0
1438	Pharmacologic heart failure treatment: A case-based review of current guidelines. Journal of the American Association of Nurse Practitioners, 2021, 33, 1042-1049.	0.5	0
1439	Heart Failure with Preserved Ejection Fraction and Cardiac Amyloidosis: Implications for Treatment. , 2021, 1, 98-102.		1
1440	Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV. Journal of the Endocrine Society, 2022, 6, bvab175.	0.1	1
1441	Natriuretic peptideâ€‘based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <sc>PARAGONâ€‘HF</sc>. European Journal of Heart Failure, 2022, 24, 672-677.	2.9	6
1442	Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Medicine, 2022, 20, 21.	2.3	5
1443	Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. International Journal of Heart Failure, 2022, 4, 75.	0.9	10
1444	Behind the Scenes of TOPCAT â€‘ Bending to Inform. , 2022, 1, .		8
1445	HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction. Korean Journal of Internal Medicine, 2022, 37, 96-108.	0.7	10
1446	QbD method to the formulation and development of a spironolactone immediate-release tablet with enhanced dissolving research. Materials Today: Proceedings, 2022, , .	0.9	0
1447	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. Diabetes Therapy, 2022, 13, 241-250.	1.2	11

#	ARTICLE	IF	CITATIONS
1448	Orthopaedic Nursing and Heart Failure. <i>Orthopaedic Nursing</i> , 2022, 41, 25-34.	0.2	0
1449	The "Obesity Paradox" in Patients With HFpEF With or Without Comorbid Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 743327.	1.1	5
1450	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	1.3	5
1451	Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. <i>Journal of Cardiac Failure</i> , 2022, 28, 1035-1039.	0.7	5
1452	Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure. <i>International Journal of Heart Failure</i> , 2022, 4, 12.	0.9	2
1453	Associations between calcium channel blocker therapy and mortality in heart failure with preserved ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1343-1351.	0.8	5
1454	Prevalence and Prognostic Significance of Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1001-1011.	2.3	25
1455	Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 303-320.	0.9	1
1456	Diastolic function: modeling left ventricular untwisting as a damped harmonic oscillator. <i>Physiological Measurement</i> , 2022, 43, 025002.	1.2	1
1457	Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas. <i>International Journal of Cardiology</i> , 2022, 352, 78-83.	0.8	2
1458	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
1459	Ischemic risk in patients with heart failure with preserved ejection fraction: A post hoc analysis of the TOPCAT data. <i>Atherosclerosis</i> , 2022, 344, 1-6.	0.4	3
1461	Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 425-438.	1.2	5
1462	Myocardial oedema: pathophysiological basis and implications for the failing heart. <i>ESC Heart Failure</i> , 2022, 9, 958-976.	1.4	12
1463	Physiological dead space during exercise in patients with heart failure with preserved ejection fraction. <i>Journal of Applied Physiology</i> , 2022, 132, 632-640.	1.2	7
1464	SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. <i>Drugs and Aging</i> , 2022, 39, 185-190.	1.3	4
1465	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. <i>Heart Failure Reviews</i> , 2022, 27, 1761-1777.	1.7	3
1466	Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. <i>Annual Review of Physiology</i> , 2022, 84, 585-610.	5.6	31

#	ARTICLE	IF	CITATIONS
1467	Beneficios de un modelo asistencial integral en pacientes con insuficiencia cardíaca y fracción de eyección preservada: Programa UMIPIC. Revista Clínica Española, 2022, , .	0.2	2
1468	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424.	1.0	144
1469	Sudden Death and Ventricular Arrhythmias in Heart Failure With Preserved Ejection Fraction. Korean Circulation Journal, 2022, 52, 251.	0.7	7
1471	Leitsymptom Dyspnoe, Leistungsschwäche. , 2022, , 121-242.		0
1472	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity. Frontiers in Physiology, 2021, 12, 785879.	1.3	3
1473	Management of heart failure in older people. Journal of Pharmacy Practice and Research, 2022, 52, 72-79.	0.5	2
1474	The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 791446.	1.1	2
1475	Age and Sex Differences in Heart Failure With Preserved Ejection Fraction. Frontiers in Aging, 2022, 3, .	1.2	4
1476	Development and Current Role of SGLT Inhibition in Cardiorenal Metabolic Syndrome. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, 593-604.	0.8	1
1478	Prognostic significance of blood urea nitrogen/creatinine ratio in chronic HFpEF. European Journal of Clinical Investigation, 2022, 52, e13761.	1.7	7
1480	The Cardiomyocyte in Heart Failure with Preserved Ejection Fraction – Victim of Its Environment?. Cells, 2022, 11, 867.	1.8	1
1481	Associations of BMI with mortality in HFpEF patients with concomitant diabetes with insulin versus non-insulin treatment. Diabetes Research and Clinical Practice, 2022, 185, 109805.	1.1	2
1482	Benefits of a comprehensive care model in patients with heart failure and preserved ejection fraction: The UMIPIC program. Revista Clínica Española, 2022, , .	0.3	3
1483	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153.	2.9	11
1484	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 2022, 24, 771-778.	2.9	7
1485	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	1
1486	Sex Differences in Therapies for Heart Failure. Current Pharmaceutical Design, 2022, 28, 1295-1303.	0.9	1
1487	Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES121008487.	0.9	21

#	ARTICLE	IF	CITATIONS
1488	Association between prognosis and the use of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 1801-1811.	1.4	2
1489	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <sc>FIDELIO&K&D</sc> trial. European Journal of Heart Failure, 2022, 24, 996-1005.	2.9	23
1490	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology, 2022, 79, 1129-1137.	1.2	36
1492	Global status and trends in heart failure with preserved ejection fraction over the period 2009-2020. Medicine (United States), 2022, 101, .	0.4	1
1493	Cell Therapy in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 2022, 8, e08.	1.2	3
1495	The Cardiovascular Pharmaceutical Cornucopia. Journal of the American College of Cardiology, 2022, 79, 1138-1140.	1.2	0
1496	Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2022, 11, e022765.	1.6	16
1497	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure, 2022, 28, 810-830.	0.7	42
1498	Aldosterone and cardiovascular diseases. Cardiovascular Research, 2023, 119, 28-44.	1.8	14
1499	Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure. JACC: Heart Failure, 2022, 10, 369-379.	1.9	8
1500	Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney International Supplements, 2022, 12, 19-26.	4.6	15
1501	Sudden cardiac death in heart failure with preserved ejection fraction: an updated review. International Journal of Arrhythmia, 2022, 23, .	0.3	2
1502	Epicardial fat and incident heart failure with preserved ejection fraction in patients with coronary artery disease. International Journal of Cardiology, 2022, 357, 140-145.	0.8	13
1503	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	1.2	314
1504	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
1505	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001062.	1.6	133
1506	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
1507	Trends in Hospital Admissions for Systolic and Diastolic Heart Failure in the United States Between 2004 and 2017. American Journal of Cardiology, 2022, 171, 99-104.	0.7	9

#	ARTICLE	IF	CITATIONS
1508	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1016-1030.	0.7	5
1509	Under-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials. <i>Journal of Cardiac Failure</i> , 2022, 28, 723-731.	0.7	3
1510	Efficacy of Renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy -from the KUNILUMI Registry Acute Cohort-. <i>Journal of Cardiology</i> , 2022, 79, 703-710.	0.8	5
1511	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2021, 100, e28448.	0.4	2
1512	Heart failure with preserved ejection fraction: An alternative paradigm to explain the clinical implications of atrial fibrillation. <i>Heart Rhythm O2</i> , 2021, 2, 771-783.	0.6	10
1513	Hospitalisations in HFpEF: More than just a matter of the heart. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13739.	1.7	0
1514	Clinical Characteristics, Treatment, and Short-Term Outcome in Patients with Heart Failure and Cancer. <i>Clinics and Practice</i> , 2021, 11, 933-941.	0.6	0
1515	Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go. <i>Cureus</i> , 2021, 13, e20359.	0.2	3
1516	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400.	1.0	8
1517	Clinical Profile-Based Pharmacological Sequencing for Heart Failure with Preserved Ejection Fraction. , 2022, 2, 72-75.		0
1518	Essential Therapy for Heart Failure with Preserved Ejection Fraction in 2022. , 2022, 2, 55-63.		0
1519	SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. , 2022, 2, 67-71.		0
1520	Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, , .	1.9	2
1521	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.	0.6	40
1522	Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 669-675.	1.1	4
1523	Abdominal Obesity Is Associated with an Increased Risk of All-Cause Mortality in Males but Not in Females with HFpEF. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-11.	1.1	2
1524	Sex and Gender-Related Issues in Heart Failure. <i>Cardiology Clinics</i> , 2022, 40, 259-268.	0.9	3
1527	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	1.0	10

#	ARTICLE	IF	CITATIONS
1528	Signaling cascades in the failing heart and emerging therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 134.	7.1	18
1530	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. <i>Heart Failure Reviews</i> , 2022, , .	1.7	5
1531	Impact of Diabetic Retinopathy on Prognosis of Patients with Heart Failure with Preserved Ejection Fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	1.1	0
1532	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	1.5	16
1533	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 149.	0.8	7
1534	Diagnostic role of echocardiography for patients with heart failure symptoms and preserved left ventricular ejection fraction. <i>Herz</i> , 2022, 47, 293-300.	0.4	3
1535	Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations. <i>European Journal of Heart Failure</i> , 2022, 24, 1418-1426.	2.9	10
1536	Management strategies in heart failure with preserved ejection fraction. <i>Herz</i> , 2022, 47, 332-339.	0.4	2
1538	Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	30
1539	A Bibliometric Analysis of Heart Failure with Preserved Ejection Fraction From 2000 to 2021. <i>Current Problems in Cardiology</i> , 2022, 47, 101243.	1.1	10
1540	New therapies for the treatment of heart failure with preserved ejection fraction. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1424-1430.	0.5	4
1541	Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment. <i>Cardio-Oncology</i> , 2022, 8, 11.	0.8	1
1542	Non-steroidal aldosterone receptor antagonism: a treatment for heart failure patients?. <i>European Journal of Heart Failure</i> , 2022, 24, 1006-1008.	2.9	0
1544	Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines. <i>European Journal of Heart Failure</i> , 2022, 24, 916-926.	2.9	18
1545	Mechanical and interventional support for heart failure with preserved ejection fraction: A review. <i>Artificial Organs</i> , 2022, , .	1.0	1
1546	Clinical predictors of hyponatremia in patients with heart failure according to severity of chronic kidney disease. <i>Wiener Klinische Wochenschrift</i> , 2022, , .	1.0	1
1547	Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study. <i>Hypertension</i> , 2022, 79, 1984-1993.	1.3	17
1549	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2186-2199.	1.4	9

#	ARTICLE	IF	CITATIONS
1550	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2022, 386, e57.	13.9	10
1551	Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	5
1552	Paradigm change in the treatment of chronic heart failure according to ESC Guide 2021: New innovative drugs in focus. <i>Timocki Medicinski Glasnik</i> , 2022, 47, 40-47.	0.0	1
1553	Impact of Sodiumâ€“Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Agingâ€“What Do We Know So Far? (A Narrative Review). <i>Life</i> , 2022, 12, 803.	1.1	11
1554	Gliflozins in the Management of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2022, 386, 2024-2034.	13.9	113
1555	Circulating Sâ€“Glutathionylated cMyBPâ€“C as a Biomarker for Cardiac Diastolic Dysfunction. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2
1556	Remodeling of cardiac metabolism in heart failure with preserved ejection fraction. <i>Current Opinion in Physiology</i> , 2022, 27, 100559.	0.9	2
1557	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. <i>Diabetes Care</i> , 2022, 45, 1670-1690.	4.3	109
1558	Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. <i>Cardiology Journal</i> , 0, , .	0.5	3
1559	Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models. <i>Circulation Research</i> , 2022, 130, 1906-1925.	2.0	45
1560	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. <i>European Journal of Internal Medicine</i> , 2022, 103, 29-35.	1.0	5
1561	A first step towards best practice recommendations for the design and statistical analyses of pragmatic clinical trials: a modified Delphi approach. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1
1562	Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. <i>Current Heart Failure Reports</i> , 2022, 19, 191-199.	1.3	2
1563	Cardiorenal Crosstalk in Patients with Heart Failure. <i>Kidney and Dialysis</i> , 2022, 2, 369-385.	0.5	0
1564	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>European Heart Journal</i> , 2022, 43, 2931-2945.	1.0	14
1565	Future scope and challenges for congestive heart failure: Moving towards development of pharmacotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	0.7	2
1566	Impact of different training modalities on highâ€“density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial. <i>ESC Heart Failure</i> , 2022, 9, 3019-3030.	1.4	3
1567	Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2023, 118, 3586-3601.	1.8	9

#	ARTICLE	IF	CITATIONS
1568	Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. <i>Cardiology and Therapy</i> , 2022, 11, 337-354.	1.1	12
1569	Can We Stop Reflexively Discontinuing Mineralocorticoid Antagonists for Patients With Heart Failure and Hyperkalemia?. <i>Journal of Cardiac Failure</i> , 2022, 28, 1464-1468.	0.7	3
1570	Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study. <i>European Journal of Pharmacology</i> , 2022, 928, 175053.	1.7	10
1571	When to Suspect Advanced Heart Failure in Heart Failure with Preserved Ejection Fraction?. , 2022, 2, 214-217.		0
1572	New strategies and therapies for the prevention of heart failure in high-risk patients. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	4
1573	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	8
1574	Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2022, 22, 87-95.	0.2	1
1575	Atrial fibrillation in heart failure patients: An update on renin-angiotensin-aldosterone system pathway blockade as a therapeutic and prevention target. <i>Cardiology Journal</i> , 2023, 30, 312-326.	0.5	3
1576	The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. <i>Clinical Science</i> , 2022, 136, 1005-1017.	1.8	5
1577	Reshaping Treatment of Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 3706.	1.0	2
1578	Diagnosis and Management of Heart Disease. , 2022, , 139-172.		0
1579	Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2023, 112, 111-122.	1.5	8
1580	Update in approaches to pulmonary hypertension because of left heart disease. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 337-342.	1.2	2
1581	Los iSGLT2 en la insuficiencia cardiaca. ¿Sus beneficios pueden extenderse a todo el espectro de la fracción de eyección?. <i>Revista Española De Cardiología (English Ed)</i> , 2022, , .	0.4	0
1582	Selected Transesophageal Echocardiographic Parameters of Left Ventricular Diastolic Function Predict Length of Stay Following Coronary Artery Bypass Graft—A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3980.	1.0	3
1583	Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	13
1584	Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?. <i>World Journal of Cardiology</i> , 2022, 14, 438-445.	0.5	4
1585	A PILOT CLINICAL TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION. <i>European Journal of Heart Failure</i> , 0, , .	2.9	4

#	ARTICLE	IF	CITATIONS
1586	Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3885.	1.0	4
1587	Salt restriction and risk of adverse outcomes in heart failure with preserved ejection fraction. <i>Heart</i> , 2022, 108, 1377-1382.	1.2	4
1588	Targeted potassium levels to decrease arrhythmia burden in high risk patients with cardiovascular diseases (POTCAST): Study protocol for a randomized controlled trial. <i>American Heart Journal</i> , 2022, , .	1.2	3
1589	Unsupervised Machine Learning for Assessment of Left Ventricular Diastolic Function and Risk Stratification. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 1214-1225.e8.	1.2	11
1590	Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	7
1591	Neutrophils and Circulating Inflammatory Biomarkers in Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2022, 178, 80-88.	0.7	1
1592	A Data Mining-Based Study on Medication Rules of Chinese Herbs to Treat Heart Failure with Preserved Ejection Fraction. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 847-854.	0.7	8
1593	Nickel-catalyzed Thioester Transfer Reaction with sp ² -Hybridized Electrophiles. <i>Journal of Organic Chemistry</i> , 2022, 87, 10003-10017.	1.7	6
1594	Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association. <i>Circulation</i> , 2022, 146, .	1.6	13
1595	The Potential Role of Renal Denervation in the Management of Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 4147.	1.0	4
1596	Insufici�ncia Card�aca com Fra��o de Eje�o Levemente Reduzida: Considera�es Terap�uticas e Justificativas dessa Renomea�o. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, 119, 124-127.	0.3	1
1597	Clinical impact of blood urea nitrogen, regardless of renal function, in heart failure with preserved ejection fraction. <i>International Journal of Cardiology</i> , 2022, 363, 94-101.	0.8	9
1599	Clinical Phenotypes of Heart Failure across the spectrum of Ejection Fraction: A Cluster Analysis. <i>Current Problems in Cardiology</i> , 2022, 47, 101337.	1.1	2
1600	Heart failure with preserved ejection fraction��Out with the old and out with the new?. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1601	Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the <sc>PARAGON�HF</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1906-1914.	2.9	10
1602	Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 379-399.	1.3	2
1603	Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm. <i>Revista Portuguesa De Cardiologia</i> , 2022, 41, 853-861.	0.2	4
1604	Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.. <i>Kardiologiya</i> , 2022, 62, 3-11.	0.3	0

#	ARTICLE	IF	CITATIONS
1605	Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. <i>Cardiovascular Research</i> , 2023, 118, 3434-3450.	1.8	49
1606	Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes. <i>Kardiologiya</i> , 2022, 62, 44-53.	0.3	6
1607	Management of Heart Failure in Patients with Chronic Kidney Disease. <i>European Cardiology Review</i> , 0, 17, .	0.7	5
1608	New concepts in heart failure with preserved ejection fraction and hypertension. <i>Current Opinion in Cardiology</i> , 2022, 37, 424-430.	0.8	1
1609	Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	19
1610	Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions. <i>CJC Open</i> , 2022, 4, 959-969.	0.7	3
1611	The importance of randomization in clinical research. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 0, , .	0.2	0
1612	Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction. <i>Circulation</i> , 2022, 146, 506-518.	1.6	47
1613	Predicting treatment response in patients with HFpEF and myocardial fibrosis. Identifying useful tools with the help of CMR. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 2209-2211.	0.2	0
1614	Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association <scp>Databaseâ€Heart</scp> Failure Center Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 2048-2062.	2.9	20
1615	SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 989-996.	1.3	7
1616	Clinical course and decisionâ€making in heart failure by preload stress echocardiography: a preliminary study. <i>ESC Heart Failure</i> , 0, , .	1.4	2
1618	Usefulness of Bâ€Type Natriuretic Peptide for Predicting the Risk of Stroke in Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	3
1619	Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 3985-3994.	1.4	8
1620	Clinical impact of beta-blockers at discharge on long-term clinical outcomes in patients with non-reduced ejection fraction after acute myocardial infarction. <i>Journal of Cardiology</i> , 2023, 81, 83-90.	0.8	1
1621	Associations of body mass index with mortality in heart failure with preserved ejection fraction patients with ischemic versus non-ischemic etiology. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1622	The Efficacy of Various Pharmacological Agents on Long-Term Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Randomized Control Trials. <i>Cureus</i> , 2022, , .	0.2	0
1623	Heart Failure with Preserved Ejection Fraction in Children. <i>Pediatric Cardiology</i> , 2023, 44, 513-529.	0.6	2

#	ARTICLE	IF	CITATIONS
1624	Why We Should Care About Who Cares for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	3
1625	Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. <i>Journal of Hypertension</i> , 2022, 40, 1918-1926.	0.3	4
1626	Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial. <i>Clinical and Translational Science</i> , 2022, 15, 2493-2504.	1.5	4
1627	Prognostic value of post-discharge depression in patients recently hospitalized with acute heart failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1628	Machine learning model for predicting 1-year and 3-year all-cause mortality in ischemic heart failure patients. <i>Postgraduate Medicine</i> , 0, , 1-10.	0.9	0
1629	Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	12
1630	Aldosterone as a Mediator of Cardiovascular Damage. <i>Hypertension</i> , 2022, 79, 1899-1911.	1.3	47
1631	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. <i>IJC Heart and Vasculature</i> , 2022, 42, 101103.	0.6	4
1632	Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 323, H861-H868.	1.5	8
1633	Novidades e Reflexões sobre o Tratamento Farmacológico da Insuficiência Cardíaca com Fração de Ejeção Preservada. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, , .	0.3	0
1634	The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.1	3
1635	Lowering Uric Acid May Improve Prognosis in Patients With Hyperuricemia and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	11
1636	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113701.	2.5	3
1637	áŽç, ©èf1/2ãªãŸã,CEãŸã;fã,â...`1/4`HFpEF1/4%ã«ãšãã,ãf•ãf-ã,ãf«ã«çç»©ã-ãŸæ,£ð€...ã±ã`ŸãCE-ãæ²»ç™,ã«ã.Ÿ. <i>Journal of JCS Ca</i>		
1638	Reading and Interpreting the Literature on Randomized Controlled Trials. , 2022, , 2197-2208.		0
1639	Mechanism of action of diuretic and anti-diuretic drugs. , 2023, , 369-390.		0
1640	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction. <i>JAMA Cardiology</i> , 2022, 7, 1067.	3.0	12
1641	Aldosterone excess and cardiorenal risk: more common than appreciated. <i>European Heart Journal</i> , 0, , .	1.0	2

#	ARTICLE	IF	CITATIONS
1642	Essen Stroke Risk Score Predicts Clinical Outcomes in Heart Failure Patients with Preserved Ejection Fraction: Evidence from the TOPCAT trial. <i>Thrombosis and Haemostasis</i> , 2023, 123, 085-096.	1.8	4
1643	Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1644	Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors. <i>Biomolecules</i> , 2022, 12, 1349.	1.8	4
1645	Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction. <i>JAMA Network Open</i> , 2022, 5, e2231963.	2.8	13
1646	Endotrophin, a Collagen VI Formationâ€œDerived Peptide, in Heart Failure. , 2022, 1, .		17
1647	Steroidal MRA Across the Spectrum of Renal Function. <i>JACC: Heart Failure</i> , 2022, 10, 842-850.	1.9	2
1649	Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	7
1650	Chronic Heart Failure. <i>Orthopaedic Nursing</i> , 2022, 41, 363-368.	0.2	1
1651	NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction. <i>Antioxidants</i> , 2022, 11, 1822.	2.2	14
1652	Update on Atrial Shunt Therapy for Treatment of Heart Failure. <i>Structural Heart</i> , 2022, 6, 100090.	0.2	2
1653	Importance of epicardial adipose tissue as a predictor of heart failure with preserved ejection fraction. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2022, 68, 1178-1184.	0.3	3
1654	SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
1655	From Structural to Functional Hypertension Mediated Target Organ Damageâ€œA Long Way to Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 5377.	1.0	5
1656	Medical Therapy for Functional Mitral Regurgitation. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	7
1657	Current Management of Heart Failure with Preserved Ejection Fraction. <i>International Journal of Angiology</i> , 2022, 31, 166-178.	0.2	0
1658	Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 1767-1777.	2.9	14
1659	Safety, Efficacy and Prognostic Benefit of Atrial Fibrillation Ablation in Heart Failure with Preserved Ejection Fraction. <i>Arrhythmia and Electrophysiology Review</i> , 0, 11, .	1.3	0
1660	Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without TypeÂ² Diabetes. <i>Advances in Therapy</i> , 2022, 39, 4837-4846.	1.3	5

#	ARTICLE	IF	CITATIONS
1661	Clinical Translation of Cardiovascular Biomarkers – A Long and Uncertain Road. , 2022, 1, .		0
1662	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. International Journal of Molecular Sciences, 2022, 23, 11336.	1.8	3
1663	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. Journal of Clinical Hypertension, 2022, 24, 1218-1225.	1.0	1
1664	Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction. Cells, 2022, 11, 2750.	1.8	0
1665	Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC: Heart Failure, 2023, 11, 76-89.	1.9	8
1666	Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients. Heart Failure Reviews, 2023, 28, 949-959.	1.7	7
1667	Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping. Current Heart Failure Reports, 0, , .	1.3	3
1668	Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection. Current Problems in Cardiology, 2022, 47, 101386.	1.1	6
1669	Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Cardiac Failure Review, 0, 8, .	1.2	2
1670	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). Eurasian Heart Journal, 2022, , 6-56.	0.2	0
1671	Heart Failure and Diabetes Mellitus: Dangerous Liaisons. International Journal of Heart Failure, 2022, 4, 163.	0.9	7
1672	Heart Failure Drug Therapy: New Treatments, New Guidelines. Texas Heart Institute Journal, 2022, 49, .	0.1	0
1673	Spirolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure. , 2022, 1, 89-100.		0
1674	The patient-reported outcome measurement in heart failure clinic trial: Rationale and methods of the PRO-HF trial. American Heart Journal, 2023, 255, 137-146.	1.2	2
1675	The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management. Current Cardiology Reports, 2022, 24, 1785-1790.	1.3	1
1676	Heart failure with preserved ejection fraction: Calculating the risk of future heart failure events and death. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
1677	Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study. ESC Heart Failure, 2023, 10, 322-333.	1.4	3
1678	Considerations in the Interpretation of Patient Reported Outcomes in Heart Failure with Reduced and Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, , .	0.7	0

#	ARTICLE	IF	CITATIONS
1679	Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	9
1680	Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial. <i>International Journal of Cardiology</i> , 2023, 370, 263-270.	0.8	2
1681	Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. <i>European Journal of Heart Failure</i> , 2023, 25, 108-113.	2.9	10
1682	An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1737-1751.	0.9	4
1684	Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists. <i>Structural Heart</i> , 2022, , 100082.	0.2	0
1685	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2022, 102, S1-S127.	2.6	246
1686	Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2023, 8, 56.	3.0	37
1687	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1957-1974.	0.9	0
1688	Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. <i>Kidney International</i> , 2022, 102, 990-999.	2.6	78
1689	Application of H<sub>2</sub>FPEF Score in Heart Failure with Preserved Ejection Fraction. <i>Advances in Clinical Medicine</i> , 2022, 12, 9871-9877.	0.0	0
1690	Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) as a Platform for Modeling Arrhythmias. , 2022, , 875-893.		0
1691	Circulating Cardiac Biomarkers in Heart Failure: A Critical Link to Biomarker-Guided Therapy. <i>EMJ Cardiology</i> , 0, , 139-147.	0.0	0
1692	Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction. <i>Hypertension Research</i> , 2023, 46, 475-484.	1.5	1
1693	Heterogeneity in multi-centre trial participating centers: Lessons from the TOPCAT trial on interpreting trial data for clinical practice. <i>Journal of Clinical Epidemiology</i> , 2022, , .	2.4	0
1694	Bibliometric and visual analysis of coronary microvascular dysfunction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1695	Hypertension management in patients with cardiovascular comorbidities. <i>European Heart Journal</i> , 2023, 44, 2066-2077.	1.0	24
1696	Pathophysiology and Management of Heart Failure in the Elderly. <i>International Journal of Angiology</i> , 0, , .	0.2	0
1697	Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Internal Medicine</i> , 2022, 182, 1278.	2.6	26

#	ARTICLE	IF	CITATIONS
1698	Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	3
1699	Does exercise training improve exercise tolerance, quality of life, and echocardiographic parameters in patients with heart failure with preserved ejection fraction? A systematic review and meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2023, 28, 795-806.	1.7	2
1700	Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys. <i>Annual Review of Medicine</i> , 2023, 74, 217-230.	5.0	4
1701	Combined Neuro-Humoral Modulation and Outcomes in Patients with Chronic Heart Failure and Mildly Reduced or Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 6627.	1.0	0
1702	Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease. <i>Kidney Diseases (Basel, Switzerland)</i> , 2023, 9, 12-25.	1.2	1
1703	The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. <i>American Journal of Hypertension</i> , 2023, 36, 135-143.	1.0	9
1704	Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 0, , .	1.7	0
1705	Flowchart for Treatment of Heart Failure with Preserved Ejection Fraction. , 2022, 2, 299-303.		0
1706	HFpEF: Evidence from Recent Clinical Trials and New Perspectives. , 2022, 2, 326-328.		0
1707	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). <i>Eurasian Heart Journal</i> , 2022, , 6-56.	0.2	0
1708	Medical Therapy for Heart Failure with Preserved Ejection Fraction. <i>Methodist DeBakey Cardiovascular Journal</i> , 2022, 18, 17-26.	0.5	1
1709	Physical Training in Heart Failure with Preserved Ejection Fraction. , 2022, 2, 310-315.		0
1710	Endothelial cell-specific mineralocorticoid receptor activation promotes diastolic dysfunction in diet-induced obese male mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2023, 324, R90-R101.	0.9	1
1711	EMPEROR-Pre - Empagliflozin and cardiovascular events in patients with heart failure and preserved ejection fraction. <i>Intervencni A Akutni Kardiologie</i> , 2022, 21, 168-172.	0.0	0
1712	Hibernation or Transformation? Challenges in Cardiovascular Drug Development. <i>Frontiers in Cardiovascular Drug Discovery</i> , 2022, , 102-140.	0.0	0
1713	Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1714	Heart Failure Burden by Autopsy, Guideline-Directed Medical Therapy, and ICD Utilization Among Sudden Deaths. <i>JACC: Clinical Electrophysiology</i> , 2023, 9, 403-413.	1.3	0
1715	Machine learning models in heart failure with mildly reduced ejection fraction patients. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0

#	ARTICLE	IF	CITATIONS
1716	Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. <i>Journal of Nephrology</i> , 0, , .	0.9	2
1718	Efficacy of guideline-directed medical treatment in heart failure with mildly reduced ejection fraction. <i>ESC Heart Failure</i> , 2023, 10, 1035-1042.	1.4	3
1719	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. <i>Cardiovascular Research</i> , 2023, 118, 3467-3481.	1.8	4
1720	Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. <i>Nature Medicine</i> , 2022, 28, 2512-2520.	15.2	5
1721	Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 845-854.	0.4	4
1722	Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1149-1160.	2.8	3
1723	Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial. <i>EBioMedicine</i> , 2022, 86, 104334.	2.7	6
1724	Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration. <i>Annals of Internal Medicine</i> , 2022, 175, 1675-1684.	2.0	4
1725	Prognostic Impact of Indeterminate Diastolic Function in Patients With Functionally Insignificant Coronary Stenosis. <i>Journal of the American Society of Echocardiography</i> , 2023, 36, 295-306.e5.	1.2	6
1726	Polypharmacy in Older People with Heart Failure: Roles of the Geriatrician and Pharmacist. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	1
1727	Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	2
1728	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. <i>ESC Heart Failure</i> , 2023, 10, 1555-1569.	1.4	3
1729	The four pillars of HFREF therapy: is it time to treat heart failure regardless of ejection fraction?. <i>European Heart Journal Supplements</i> , 2022, 24, L10-L19.	0.0	6
1730	Effect of arotinolol on chronic heart failure: A systematic review and meta-analysis of randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
1731	Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?. <i>Revista Romana De Cardiologie</i> , 2022, 32, 167-173.	0.0	1
1732	Biological Activity of a 4-Hydroxy-Furanyl-Benzamide Derivative on Heart Failure. <i>Drug Research</i> , 0, , .	0.7	0
1733	Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest. <i>Journal of Clinical Medicine</i> , 2023, 12, 693.	1.0	4
1734	Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease. <i>Advances in Clinical Medicine</i> , 2023, 13, 427-435.	0.0	0

#	ARTICLE	IF	CITATIONS
1735	Non-invasive and contemporaneous cardiac imaging in heart failure. <i>British Journal of Nursing</i> , 2023, 32, 29-36.	0.3	0
1736	Development and validation of prediction models for incident atrial fibrillation in heart failure. <i>Open Heart</i> , 2023, 10, e002169.	0.9	0
1737	Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization. <i>JACC: Heart Failure</i> , 2023, 11, 596-606.	1.9	4
1738	Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 183-191.	1.4	12
1739	Renin-Angiotensin-Aldosterone System as an Old New Target in Heart Failure Therapy. , 2023, , 307-330.		1
1740	Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. <i>Drugs in Context</i> , 0, 12, 1-16.	1.0	2
1742	Diet modification reverses diastolic dysfunction in rats with heart failure and preserved ejection fraction. , 2023, 3, 100031.		1
1743	Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, 44-51.	0.6	4
1744	Effect of eplerenone on clinical stability of Japanese patients with acute heart failure. <i>International Journal of Cardiology</i> , 2023, 374, 73-78.	0.8	2
1745	Possibility of using European (HFA-PEFF) and American (H2FPEF) algorithms for diagnosing heart failure with preserved ejection fraction in Russian clinical practice. <i>Kardiologiia</i> , 2022, 62, 4-10.	0.3	4
1746	Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. <i>Cardiology in Review</i> , 2024, 32, 114-123.	0.6	4
1747	Arterielle Hypertonie. , 2022, , 155-204.		0
1748	Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease-----Balance of efficacy and risk. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1749	Non-invasive telemonitoring and quality of life in heart failure: part one" developing a mixed-methods systematic review protocol. <i>British Journal of Cardiac Nursing</i> , 2023, 18, 1-10.	0.0	1
1751	Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	6
1752	Physiology and pharmacology of ATP-releasing pannexin 1 channels. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1753	Heart Failure Pharmacological Management: Gaps and Current Perspectives. <i>Journal of Clinical Medicine</i> , 2023, 12, 1020.	1.0	8
1754	Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. <i>European Heart Journal</i> , 2023, 44, 668-677.	1.0	4

#	ARTICLE	IF	CITATIONS
1755	Cardiovascular Disease in Obstructive Sleep Apnea: Putative Contributions of Mineralocorticoid Receptors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2245.	1.8	0
1756	Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
1758	Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2023, 10, 1771-1780.	1.4	5
1761	Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-14.	2.2	4
1762	Heart Failure with Preserved vs. Reduced Ejection Fraction: Patient Characteristics, In-hospital Treatment and Mortality—DanAHF, a Nationwide Prospective Study. <i>Journal of Cardiovascular Translational Research</i> , 0, , .	1.1	0
1763	Prognostic impact of cardiovascular polypharmacy on octogenarians with heart failure with preserved ejection fraction. <i>International Journal of Cardiology</i> , 2023, 378, 55-63.	0.8	2
1765	Latest Standard Management for Heart Failure with Guideline-Directed Medical Therapy (GDMT). , 2022, 3, 35-40.		0
1766	Left ventricular hypertrophy as a predictor of cardiovascular outcomes after transcatheter aortic valve replacement. <i>ESC Heart Failure</i> , 2023, 10, 1336-1346.	1.4	2
1767	Spirolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials. <i>International Journal of Cardiology</i> , 2023, 377, 86-88.	0.8	4
1768	Heart Failure With Stable Mildly-reduced Ejection Fraction: Prognosis and Predictors of Outcomes. <i>Current Problems in Cardiology</i> , 2023, 48, 101631.	1.1	3
1769	The controversial role of beta-blockers in heart failure with preserved ejection fraction. , 2023, 243, 108356.		4
1770	Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 157-166.	0.7	2
1771	Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles. <i>Biomolecules</i> , 2023, 13, 321.	1.8	2
1772	I. General: Read Treatment Algorithm for Heart Failure in the Guideline Focused Update; 2. Heart Failure with Preserved Ejection Fraction (HFpEF). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 213-220.	0.0	0
1773	Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. <i>Kidney360</i> , 2023, 4, e486-e495.	0.9	1
1774	Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 911-922.	1.5	3
1775	Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	8
1776	Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model. <i>Journal of Personalized Medicine</i> , 2023, 13, 335.	1.1	4

#	ARTICLE	IF	CITATIONS
1777	Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors. <i>Circulation</i> , 2023, 147, 635-637.	1.6	0
1778	The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. <i>Current Pharmaceutical Design</i> , 2023, 29, 481-493.	0.9	1
1779	Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model. <i>Heart</i> , 2023, 109, 1231-1240.	1.2	6
1780	Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic. <i>European Heart Journal</i> , 2023, 44, 1544-1556.	1.0	13
1781	Editorial: The role of sex in heart failure and transplantation, volume II. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
1782	Sudden Death in Men Versus Women with Heart Failure. <i>Current Heart Failure Reports</i> , 2023, 20, 129-137.	1.3	2
1783	Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction. <i>CJC Open</i> , 2023, 5, 380-391.	0.7	1
1784	Discriminative Role of Invasive Left Heart Catheterization in Patients Suspected of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	5
1785	The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis. <i>ESC Heart Failure</i> , 2023, 10, 1822-1834.	1.4	3
1786	Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 114.	0.8	0
1787	Leveraging Biomarkers for Precision Medicine in Heart Failure. <i>Journal of Cardiac Failure</i> , 2023, 29, 459-462.	0.7	2
1788	Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 827.	3.8	82
1789	Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2023, 11, 1103-1117.	1.9	9
1790	Heart failure therapy challenges in obese patients. <i>Medicinski Glasnik Specijalne Bolnice Za Bolesti Atitaste i Bolesti Metabolizma Zlatibor</i> , 2023, 28, 21-42.	0.1	0
1791	Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. <i>ESC Heart Failure</i> , 2023, 10, 1499-1530.	1.4	8
1792	Heart Failure with Preserved Ejection Fraction. , 2023, , 89-106.		0
1794	Heart failure: pathophysiology and the emergence of novel therapies. , 2023, , 441-458.		0
1795	Interpretation of the central aortic pressure waveform in elderly patients with aortic stenosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
1796	Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fraction. <i>Pharmacotherapy</i> , 0, , .	1.2	1
1797	Cardiac rehabilitation utilization, barriers, and outcomes among patients with heart failure. <i>Heart Failure Reviews</i> , 2023, 28, 1239-1249.	1.7	5
1798	Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Chronic Heart Failure. , 0, 2, .		4
1799	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. <i>Korean Circulation Journal</i> , 2023, 53, 217.	0.7	4
1800	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. <i>International Journal of Heart Failure</i> , 2023, 5, 66.	0.9	9
1801	CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. <i>Wiadomości Lekarskie</i> , 2023, 76, 645-650.	0.1	0
1802	Updates in Cardiorenal Syndrome. <i>Medical Clinics of North America</i> , 2023, , .	1.1	1
1803	Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. <i>Cardiac and Vascular Biology</i> , 2023, , 229-264.	0.2	0
1804	2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1835-1878.	1.2	74
1805	Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1810-1834.	1.2	61
1806	Diastolic heart failure: 20 years later. Current issues of pathogenesis, diagnosis and treatment of heart failure with preserved LVEF. <i>Kardiologiya</i> , 2023, 63, 3-12.	0.3	6
1807	Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score "Matched Analysis of the TOPCAT Americas Trial. <i>Europace</i> , 2023, 25, .	0.7	2
1820	Empagliflozin in Diastolic Heart Failure (EMPEROR)-2021. , 2023, , 65-68.		0
1847	Renin-Angiotensin-Aldosterone System in Diabetic Cardiovascular Complications. <i>Contemporary Cardiology</i> , 2023, , 863-894.	0.0	0
1850	Stem Cells in Heart Failure: Future Perspective. , 2023, , 491-514.		0
1854	Heart Failure Management in Developing Countries. , 2023, , 1-28.		0
1869	Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines. <i>Cardiology and Therapy</i> , 0, , .	1.1	0
1900	Renin Angiotensin Aldosterone System Blockers. , 2024, , 258-273.		0

#	ARTICLE	IF	CITATIONS
1917	Editorial: The role of metabolic syndrome and disorders in cardiovascular disease. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
1923	Natriuretic peptide testing strategies in heart failure: A 2023 update. <i>Advances in Clinical Chemistry</i> , 2023, , .	1.8	0
1936	Management of Cardiovascular Disease in the Elderly. , 2023, , 1-41.		0
1954	Chronische Herzinsuffizienz. , 2024, , 98-117.		0
1973	Management of Cardiovascular Disease in the Elderly. , 2024, , 343-383.		0
1975	Arterielle Hypertonie. , 2023, , 177-226.		0
1982	The Role of Drug Therapy in Lowering Mortality and Morbidity: From High-Risk Hypertension to Established Heart Failure. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 391-408.	0.1	0
1983	Heart Failure with Preserved Ejection Fraction: Current Management and Future Strategies Pre-Heart Failure. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 477-489.	0.1	0
1985	Unmet Needs in Drug Treatment of Heart Failure in Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 409-422.	0.1	0
1986	Treating Hypertension Complicated with Heart Failure: Going Beyond the Numbers. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 339-355.	0.1	0